Virginia Commonwealth University

VCU Scholars Compass
Theses and Dissertations

Graduate School

2018

ASSOCIATION BETWEEN POLYPHARMACY AND FUNCTIONAL
STATUS IN COMMUNITY-DWELLING OLDER ADULTS
Duaa M. Bakhshwin

Follow this and additional works at: https://scholarscompass.vcu.edu/etd
© The Author

Downloaded from
https://scholarscompass.vcu.edu/etd/5356

This Dissertation is brought to you for free and open access by the Graduate School at VCU Scholars Compass. It
has been accepted for inclusion in Theses and Dissertations by an authorized administrator of VCU Scholars
Compass. For more information, please contact libcompass@vcu.edu.

© Duaa

M. Bakhshwin
2018
All Rights Reserved

ASSOCIATION BETWEEN POLYPHARMACY AND FUNCTIONAL STATUS IN
COMMUNITY-DWELLING OLDER ADULTS
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of
Philosophy at Virginia Commonwealth University

By Duaa M. Bakhshwin, MS, MBBS

Major Director: Patricia W. Slattum, Pharm.D., PhD
Professor
Department of Pharmacotherapy and Outcomes Science

Virginia Commonwealth University
Richmond, VA
April, 2018

ii

Acknowledgement

First, I am grateful to The Almighty GOD for helping me and giving me all I need to
complete this chapter in my life. I would like to express my special thanks to my advisor Dr.
Patricia Slattum who gave me the opportunity to successfully complete this project. She has
given me valuable support and suggestions. She is my role model and she was a great example
for a mentor, a teacher and an advisor. I would also like to express a deep sense of thanks to my
committee members. Dr. D‘Aarcy Mays for his patience and continuous support. He always
answered my questions with a great smile and his door is always open for his students. Dr.
Pugsley who is a great teacher, and who has a unique way in elaborating the information with a
sense of humor. She always wants her students to understand and she helps them correct their
mistakes. Dr. Peron for helping me out choosing and refining my project and for her time and
efforts. She always put a smile on anyone around her. Dr. Nadpara for accepting to work in my
committee and for your expertise and patience.

A special thank for my mom Samar Alsaggaf and dad Mohamed Bakhshwin (May his
sole reset in peace). They always believed in me, and they raised me to be a special independent
woman. My mom’s continuous support and unconditional love were my shore that held me up
whenever I felt down. My husband Mahmoud who was patient and supported me despite the
long-distance relationship we had. My son Alhussein who was my inspiration and gave strength

iii
through my stay in the US. His words (Mom you are everything, you are mom and dad and a
student, you are strong) and (Mom do not cry you have me) kept me going.
I am greatly thankful for my family and friends. They were my support system and they
were always there when I needed them. Without their love and support, it would have been
impossible to successfully complete this project. Love you all!
I will also want to acknowledge myself for staying strong, facing life, and being patient. I
went through many obstacles but with GOD willing, I overpassed it. I am excited to start my
next chapter in my life as a faculty member, a teacher a mentor and a wife.

iv

Table of contents

List of Tables .................................................................................................................. vii
List of figures ................................................................................................................... xi
List of abbreviation ........................................................................................................ xii
Abstract .......................................................................................................................... xiv
Chapter 1 Introduction .....................................................................................................1
1.1 Polypharmacy definition ................................................................................1
1.2 Polypharmacy prevalence ..............................................................................3
1.3 Polypharmacy risk factors and clinical consequences ..................................3
1.4 Functional status ............................................................................................. 4
1.5 Rate of functional impairment and need for caregiver help .......................5
1.6 Polypharmacy and functional status ............................................................. 6
1.7 Significance ...................................................................................................... 7
1.8 Specific aims .....................................................................................................8
Chapter 2 Literature review ..........................................................................................11
2.1 Literature review ..........................................................................................11
2.2 Gaps in the literature ....................................................................................19
Chapter 3 Methodology ...................................................................................................21
3.1 Data source ....................................................................................................21

v
3.2 Study design ...................................................................................................22
3.3 Data merge ......................................................................................................22
3.4 Study population ...........................................................................................23
3.5 Study variables ..............................................................................................24
3.5.1 Main exposure .......................................................................................24
3.5.2 PDS and HWB variables ......................................................................25
3.5.3 Main outcome ........................................................................................25
3.5.4 HRS variables ........................................................................................26
3.5.5 Health conditions ..................................................................................28
3.6 Statistical analysis .........................................................................................29
3.7 Missing data ...................................................................................................30
Chapter 4 Results ............................................................................................................32
Aim 1: Descriptive results ..................................................................................32
Aim 2: To assess the cross-sectional relationship between polypharmacy and
functional status using a large nationally-representative dataset ...............................39
Aim 3: To assess the longitudinal relationship between polypharmacy and functional
status using a large nationally-representative dataset .................................................66
Sensitivity analysis ...............................................................................................77
Aim 4: To identify potential confounders of the relationship between polypharmacy
and functional status ........................................................................................................87
Chapter 5 Discussion ......................................................................................................89
5.1 Descriptive data discussion ..........................................................................89
5.2 Functional status and polypharmacy in cross-sectional analyses .............92

vi
5.3 Confounders in cross-sectional analyses .....................................................93
5.4 Functional status and polypharmacy in longitudinal analyses ..................97
5.5 Confounders in longitudinal analyses .........................................................98
5.6 Strength and limitation ...............................................................................100
5.7 Conclusion ...................................................................................................101
5.8 Future directions .........................................................................................102
Reference ........................................................................................................................106
Appendix ........................................................................................................................117
VITA ...............................................................................................................................123

vii

List of Tables

Table 2.1: Studies examining the relationship between polypharmacy and functional status .......16
Table 2.2: Studies examining the relationship between PIMs and functional status ....................18
Table 3.1: HRS variables considered in the study .........................................................................26
Table 4.1: Baseline and endline characteristics of the study population 2004 -2008 ....................33
Table 4.2: The most commonly prescribed medications at baseline ............................................35
Table 4.3: The source for obtaining prescribed medications from most common to least common
source .............................................................................................................................................36
Table 4.4: The source of prescribed medications insurance ..........................................................37
Table 4.5: Self-reported side effects, unwanted reactions, and the action taken in response to this
reaction ..........................................................................................................................................38
Table 4.6: Demographic and functional status-related factors, grouped by ADL difficulty and no
difficulty ........................................................................................................................................39
Table 4.7: Bivariate associations between participants’ study variables and ADL at the baseline
(2004) ............................................................................................................................................43
Table 4.8: The predictor variables in the cross-sectional final model for ADL at baseline ..........46
Table 4.9: The adjusted odds ratio of the predictor variables in the cross-sectional final model for
ADL at baseline ............................................................................................................................47

viii
Table 4.10: Bivariate associations between participants’ study variables and ADL at the endline
(2008) .............................................................................................................................................49
Table 4.11: The predictor variables in the cross-sectional final model for ADL at endline .........52
Table 4.12: The adjusted odds ratio of the predictor variables in the cross-sectional final model
for ADL at endline .........................................................................................................................53
Table 4.13: Bivariate associations between participants’ study variables and IADL at the baseline
(2004) ............................................................................................................................................55
Table 4.14: The predictor variables in the cross-sectional final model for IADL at baseline .......58
Table 4.15: The adjusted odds ratio of the predictor variables cross-sectional final model for
IADL at baseline ...........................................................................................................................59
Table 4.16: Bivariate associations between participants’ characteristics and IADL at the endline
(2008) ............................................................................................................................................61
Table 4.17: The predictor variables in the cross-sectional final model for IADL at endline ........64
Table 4.18 The adjusted odd ratios of the predictor variables in the cross-sectional final model
for IADL at endline .......................................................................................................................65
Table 4.19: Different models to evaluate the relationship between polypharmacy status and
functional status after 4 years .......................................................................................................66
Table 4.20: Final model 1 for longitudinal analysis of ADL at endline and controlling for
baseline functional-related variables and polypharmacy at baseline ............................................68
Table 4.21: Final model 2 for longitudinal analysis of ADL at endline and controlling for
baseline functional-related variables and polypharmacy at both baseline and endline .................69
Table 4.22: Final model 3 for longitudinal analysis of IADL at endline and controlling for
baseline functional-related variables and polypharmacy at baseline .............................................70

ix
Table 4.23: Final model 4 for longitudinal analysis of IADL at endline and controlling for
baseline functional-related variables and polypharmacy at both baseline and endline .................71
Table 4.24: Different models to evaluate the relationship between polypharmacy status and
functional status after 2 years .......................................................................................................72
Table 4.25: Final model 5 for longitudinal analysis of ADL at endline and controlling for midline
functional-related variables and polypharmacy at midline ...........................................................73
Table 4.26: Final model 6 for longitudinal analysis of ADL at endline and controlling for midline
functional-related variables and polypharmacy at both midline and endline ...............................74
Table 4.27: Final model 7 for longitudinal analysis of IADL at endline and controlling for
midline functional-related variables and polypharmacy at midline ..............................................75
Table 4.28: Final model 8 for longitudinal analysis of IADL at endline and controlling for
midline functional-related variables and polypharmacy at both midline and endline .................76
Table 4.29: Different models to evaluate the relationship between polypharmacy status and
functional status after 4 years using different polypharmacy cut-offs ..........................................78
Table 4.30: Final model 9 for longitudinal analysis of ADL at endline and controlling for
baseline functional-related variables and polypharmacy and excessive polypharmacy at baseline
........................................................................................................................................................79
Table 4.31: Final model 10 for longitudinal analysis of ADL at endline and controlling for
baseline functional-related variables and polypharmacy and excessive polypharmacy at baseline
and at endline ................................................................................................................................80
Table 4.32: Final model 11 for longitudinal analysis of IADL at endline and controlling for
baseline functional-related variables and polypharmacy and excessive polypharmacy at baseline
........................................................................................................................................................81

x
Table 4.33: Final model 12 for longitudinal analysis of IADL at endline and controlling for
baseline functional-related variables and polypharmacy and excessive polypharmacy at baseline
and at endline ................................................................................................................................81
Table 4.34: Final Model 13 for linear regression model of ADL at endline and controlling for
baseline functional-related variables and number of medications at baseline ...............................83
Table 4.35: Final Model 14 for linear regression model of ADL at endline and controlling for
baseline functional-related variables and number of medications at baseline and endline ...........84
Table 4.36: Final Model 15 for linear regression model of IADL at endline and controlling for
baseline functional-related variables and number of medications at baseline ...............................85
Table 4.37: Final model 16 for linear regression model of IADL at endline and controlling for
baseline functional-related variables and number of medications at baseline and endline ...........85

xi

List of Figures

Figure 4.1 Prescription coverage and payment .................................................................37
Figure 5.1 Guidelines for standard care in community-dwelling older adults ...............105

xii

List of Abbreviations

ADL

Activities of daily living

CESD

Center for Epidemiologic Studies Depression

CI

Confidence Interval

HRS

Health and Retirement Study

IADL

Instrumental activities of daily living

IRB

Institutional Review Board

MAR

Missing at random

MCAR

Missing completely at random

MMSE

Mini mental state examination

MNAR

Missing not at random

NHAT

National Health and Aging Trends Study

OTC

Over-the-counter

PIM

Potentially inappropriate medication

Rx

Prescription medication

SPPB

Short physical performance battery

SRH

Self-reported health

START

Screening tool to alert prescribers to right treatments

xiii
STOPP

Screening tool for older people's prescriptions

Abstract

ASSOCIATION BETWEEN POLYPHARMACY AND FUNCTIONAL STATUS IN
COMMUNITY-DWELLING OLDER ADULTS
By Duaa M. Bakhshwin, MS, MBBS
Virginia Commonwealth University, 2018
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of
Philosophy at Virginia Commonwealth University
Major Director: Patricia W. Slattum, Pharm.D., PhD
Professor
Department of Pharmacotherapy and Outcomes Science

Background: Polypharmacy has no consensus definition in the literature. Previously used
definitions include those based on the number of medications and those based on unnecessary or
inappropriate medication use. Polypharmacy has been associated with increased risk of disability
and functional limitations that impair a person's ability to live independently. Older adults are a
population of interest as they are at increased risk for both polypharmacy and functional
impairments. Understanding the relationship between polypharmacy and functional impairment

in older adults could help health care providers and policy makers to target an at-risk population
for interventions.

Objectives:
1) To assess the relationship between the number of medications taken and functional status
in community-dwelling older adults using a nationally representative dataset.
2) To assess the change in the relationship between the number of medications taken and
functional status over time (2 years and 4 years).
3) To study confounders of the relationship between polypharmacy and functional status.
Methods: Data came from the Health and Retirement Study (HRS), collected in the following
years: 2004, 2006 and 2008. The primary outcome was functional limitation as measured using
the following validated tools: activities of daily living and instrumental activities of daily living
(ADL and IADL). The exposure under study was polypharmacy status (no polypharmacy: <5
prescribed medications, and polypharmacy: ≥5 prescribed medications). Both cross-sectional and
longitudinal models were used to examine different aspects of the relationship between
polypharmacy and functional status.
Results: A total sample size of 1,545 was included in our study. The prevalence of
polypharmacy was 35.9% at the beginning of the study. Polypharmacy status was significantly
associated with functional decline in both the cross-sectional and longitudinal analyses after
controlling for confounders. Self-reported health (SRH) and light exercise were associated with
functional decline in all cross-sectional analyses. Age, arthritis, and SRH were also associated

with functional decline in all longitudinal analyses. Other confounders were also associated with
functional decline.
Conclusion: Polypharmacy, defined as the use of more than five prescribed medications is a
significant risk factor for functional decline in community-dwelling older adults.

Chapter 1 Introduction

Aging is commonly associated with an increase in chronic conditions and medication
usage. More than 62% of adults aged 65-74 years old experience multiple chronic diseases
(Jokanovic et al. 2015). More than 81.5% of older adults aged 85 years and older have multiple
chronic diseases such as diabetes, hypertension, arthritis, heart diseases, and cancer (Jokanovic et
al. 2015; Quiñones et al. 2016). As chronic conditions increase with aging, medication usage also
increases. One of the main concerns that occurs with medication usage is polypharmacy.
1.1 Polypharmacy definition
Polypharmacy has no consensus definition in the literature. The definition varies, and
there are two main ways to define polypharmacy. The first way depends on the number of
medications taken, with commonly-used cutoffs defining polypharmacy as the use of five or
more medications, excessive polypharmacy as the use of ten or more medications, and oligopharmacy as the use of less than five medications (Gnjidic et al. 2012; Jyrkkä et al. 2011a). The
numeric definition is considered to be simple and is used often in practice settings. The second
definition considers unnecessary or potentially inappropriate use of medications (PIM), including
duplication of medications, inappropriate dosing, under-prescribing, adverse drug reactions,
drug-drug or drug-disease interactions, unnecessary medications, or (for older adults) the use of
medications on the Beer’s list, which is a list of medications where the risks generally outweigh
the benefits for most older adults (Fulton et al. 2005; Turner et al. 2015). Some definitions
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consider only the number of prescribed medications, while others include over-the-counter
(OTC) medications. The most common meaning of polypharmacy is the use of multiple
medications. Multiple medications do not always have to be problematic ( Levy 2017). It is
sometimes appropriate with no need for modification. Some older adults are on multiple
medications and they are healthy, while others would be better off if their medications were
fewer ( Levy 2017).
I will be using the number of prescription medications that are taken on a regular basis
(every day, every week, etc.) in the last year by participants (excluding OTC, herbal, or
nutritional supplement numbers) as a measure to assess drug burden. An advantage of using the
number of medications is the simplicity of measuring polypharmacy by this method, which is
why this approach is widely used in research and clinical settings. Also, it is a quick screening
tool that does not need excessive effort, a complicated equation, or software to calculate in
clinical practice. It is a quick screening tool that could be used to identify individuals in need of
intervention, and should not increase burden on the healthcare system. The number of
medications should ideally include prescribed medications, OTC, herbals, and nutritional
supplements that are used regularly (Sharma et al. 2016). Unfortunately, use of as needed and
nonprescription products may not be clearly documented in the patient’s medical record or in
databases used for this research.
There are other alternative measures of assessing drug burden and they mainly look for
PIM. For example, the Beer’s list contains more than 110 PIM and 60 drug-diseases for older
adults to avoid. Other examples are a screening tool for older people's prescriptions (STOPP)
which contains 80 indicators for appropriate prescribing, and a screening tool to alert prescribers
to right treatments (START) (Barry et al. 2007; Sharma et al. 2016). PIM is a good way to
2

measure drug burden and individually assess each patient’s needs. However, the disadvantage of
PIM is that it has many different tools that are time consuming to administer, are not widely used
in clinical settings, require training for healthcare providers, and need to be individualized for
each patient. Since assessing PIM’s use requires individual assessment of each participant’s
prescription list and health history, it can be difficult to implement in secondary datasets and
electronic health records that may be missing some of the necessary information. However,
PIM’s use is one of the consequences of polypharmacy that should be evaluated in future studies
(Lau et al. 2011; Lau et al. 2010).

1.2 Polypharmacy prevalence
The trend of prescribed medication usage by US community-dwelling older adults has
been increasing from 1988 to 2010. At least 90% of older adults are taking at least one
prescribed medications. In the recent studies, the prevalence of older adults taking more than five
medications is 36% to 39%. This percentage has tripled between 1988 to 2010 from 12.8% to
39.0%. This means that 1 in 3 older adults age 65 or older take five or more prescription
medications. When adding OTC and supplement usage, the prevalence of older adults age 65 or
older taking five or more medications increases to 67% (Charlesworth et al. 2015; Levy 2017).
Polypharmacy is also recognized as the most important risk factor for having PIM (Blanco-Reina
et al. 2015; Redston et al. 2018). 42.6% community-dwelling older adults had at least one PIM
(Davidoff et al. 2015). The prevalence of PIM in older adults living in long-term care range from
21.3% to 63.0% using the 2003 Beers criteria (Redston et al. 2018). The prevalence of PIM in
Europe is 22.6% for community-dwelling older adults (Tommelein et al. 2015).
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1.3 Polypharmacy risk factors and clinical consequences
Several factors are known to be associated with increased likelihood of polypharmacy,
including old age, sex, chronic diseases, multiple prescribers, cognitive impairment and
cardiovascular conditions (Jokanovic et al. 2015). Older adults often experience these risk
factors. Polypharmacy has been associated with many negative outcomes in older adults,
including increased risk of falls, functional decline, frailty, disability, drug-related problems, and
higher health costs (Maher et al. 2014). These negative outcomes are observed in older adults in
part due to physiological changes associated with aging including decreased hepatic and renal
function, changes in body composition, decline in baseline performance and decreased
homeostatic reserve. These physiological changes can cause changes in drug pharmacokinetics
(absorption, distribution, metabolism, and elimination), or pharmacodynamics (receptor and drug
action on the body) often resulting in increased drug exposure and exaggerated drug response
(Bushardt et al. 2008).

1.4 Functional status
Functional status, the ability to perform typical daily activities, is an important aspect of
quality of life and independent living in older adults. Functional status reflects the health status
and independency of people. It is measured in different ways, most often assessing ability to
performing activities of daily living (ADL). The most commonly used measure of ADL is the
basic activities of daily living ADL: toileting, bathing, dressing, walking across a room, getting
in or out of bed, and eating as defined by Katz (Katz & Akpom 1976) . Another common
measure is instrumental activities of daily living (IADL), which examines the ability to do more
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complex activities such as administration of own medications, food preparation, shopping, using
the telephone, and managing money. A third way of examining functional status is to assess
mobility by asking about the ability of walking several blocks, walking one block, walking
across the room, climbing several floors of stairs, and climbing one flight of stairs. Mobility is
often one of the first areas to decline (Peron et al. 2011).

1.5 Rate of functional impairment and need for caregiver help
Physical impairment may impact a person’s ability to function independently. Some of the risk
factors for functional decline are diabetes, hypertension , heart problems, disease burden,
depression, sedentary lifestyle, weight problems, and vision impairment (Dunlop et al. 2005;
Stuck et al. 1999). One study analyzed the 2011 National Health and Aging Trends Study
(NHATS), a study supported by the National Institute of Aging that collects information on older
adults in all of the following settings: community, residential care, and nursing home in the USA.
It collects comprehensive information about participants’ needs and disability, and it reported
that 61.5% of adults age 65 and older had no difficulties performing ADL, 19.6 % had difficulty,
and 28.7% received help from another person with ADL. The study also looked at IADL and
reported that 62.8% of adults age 65 and older had no difficulties doing IADL, 12.4% had
difficulty, and 24.8% received help from another person with IADL (Freedman & Spillman
2014( . Overall, 75% of older adults receiving help were community-dwelling, whereas 15%
lived in assisted living and 10% lived in a nursing home setting (Schulz et al. 2016).
Another study reported that 35.5% of community-dwelling older adults aged 65 years and
older have disabilities including: vision, self-care, independent living, mobility, and cognition
5

disabilities. However, this study did not address the specific type of functional limitation or
condition associated with disabilities (Courtney-Long et al. 2015). Acccording to the Disability
Statistics Organization, 7.6 % of commumity-dwelling adults aged 65 to 74 in the USA reported
an independent living disability in 2016, while 24.8% of adults above 75 reported an
independent living disability (K. Lisa Yang and Hock E. Tan 2018).

1.6 Polypharmacy and functional status
Polypharmacy may increase the risk of functional disability and impair a person’s ability
to perform ADL thus threatening older adults’ independence. A narrative review examined five
studies looking at the relationship between functional decline in older adults and suboptimal
prescribing, which was defined as “underuse or overuse of medications or prescribing potentially
inappropriate medications (PIM)” (Peron et al. 2011). All of the studies included in the review
were longitudinal, and the majority were conducted in community-dwelling older adults. In the
studies that examined some measure of PIM, two reported an association between PIM and
functional decline, and one reported no association (Hanlon et al. 2002; Pugh et al. 2008;
Corsonello et al. 2009). Several studies assessing the relationship between polypharmacy and
functional status have been conducted since this narrative review. One study used a longitudinal
design to evaluate whether polypharmacy (5 or more prescribed drugs) was associated with
functional decline among community-dwelling older adults with dementia, and assessed whether
this association may be modified by PIM (defined as use of medications on the Beer’s list) (Lau
et al. 2011). The results showed that participants with dementia and polypharmacy are more
likely to have lower functional status in the following visit. PIM did not increase the associated
risk, and drugs to avoid in the Beers’ list did not show association with functional decline (Lau et
6

al. 2011). Another study showed that drug interactions impair functional status as measured by
gait speed (a measure of mobility) in community-dwelling older adults (Naples et al. 2016).
Since it is not ethical nor feasible to do controlled trials on older adults and expose them to
multiple medications experimentally, an observational study is the best choice for looking at
polypharmacy in older humans. An experimental study using groups of young and old male mice
given five commonly used medications (simvastatin, metoprolol, omeprazole, acetaminophen,
and citalopram) for 2-4 weeks showed that polypharmacy impaired mobility, balance, and
strength in older male mice. The study authors noted that the relationship between physiological
changes in aging and body response to medications might influence the relationship between
polypharmacy and functional decline (Huizer-Pajkos et al. 2016).
Although existing literature supports the idea of an association between polypharmacy
and functional status, many of the current studies suffer from limitations such as the use of small
samples. Additionally, although some longitudinal studies exist, none have used a nationallyrepresentative sample. The objective of this study was to use longitudinal data to investigate
whether polypharmacy (defined using the number of prescribed medications) increases the risk
of functional impairment, using a large nationally-representative sample of older adults in the
USA.
1.7 Significance
Prescribing in older adults is challenging, not only because of age-related physiological
changes, but also due to the need to weigh the benefit against the potential for harm in patients
with multimorbidity and polypharmacy (Holmes et al. 2006). One of the main goals in treating
older adults is the preservation of independence. It is important to mention that functional
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impairment could be reversed by rehabilitation and controlling for disability risk factors like
polypharmacy and depression (Pamoukdjian et al. 2017; Lin et al. 2012). One study showed that
de-prescribing showed a significant difference in ADL between the control and intervention
groups (Wehling et al. 2016; Thillainadesan et al. 2018). Based on the current published
literature, polypharmacy may be an important risk factor for functional decline, but further
research is needed to evaluate the impact of polypharmacy and to understand what other risk
factors play a role in functional impairment along with polypharmacy. Likewise, most of the
previous studies control only for the number of chronic conditions and they do not look at the
relationship between functional decline and each chronic condition. To help advance this area of
research, I studied functional status as the primary outcome measure and assessed its association
with polypharmacy. Functional status is one of the quick screening tools that can predict
institutionalization and death (Saliba et al. 2000). This study provides a rigorous extension of
existing literature using longitudinal data and a large nationally-representative sample. Further
examination of the relationship between polypharmacy and functional status may lead to new
information which could help health care providers and policy makers target at risk populations
for interventions and help older adults maintain independence.
1.8 Specific aims
The hypothesis guiding this research is that there is an association between polypharmacy
and functional status in community dwelling older adults. The specific aims are to:
1. To determine the prevalence of prescription medication usage and adverse effects among
community-dwelling US older adults
a) To determine the prevalence of prescription medication use and baseline
characteristics among community-dwelling US older adults
8

b) To assess the access to prescription medications among US older adults including:
access to pharmacies, source of prescription drug insurance, and costs covered by
insurance
c) To determine the prevalence of self-reported side effects and unwanted reactions, and
to understand the consequence of these adverse drug reactions (e.g. stopping or
cutting down mediations, visiting the doctor’s office, or admission to the hospital or
the emergency room)
2. To assess the cross-sectional relationship between polypharmacy and functional status
using a large nationally-representative dataset
a) To assess the relationship between polypharmacy status and functional status
measured by ADL in community-dwelling older adults in 2004
b) To assess the relationship between polypharmacy status and functional status
measured by ADL in community-dwelling older adults in 2008
c) To assess the relationship between polypharmacy status and functional status
measured by IADL in community-dwelling older adults in 2004
d) To assess the relationship between polypharmacy status and functional status
measured by IADL in community-dwelling older adults in 2008

3. To assess the longitudinal relationship between polypharmacy and functional status using
a large nationally-representative dataset
a) To assess the relationship between polypharmacy status and functional status in
community-dwelling older adults over time (4 years)
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b) To assess the relationship between polypharmacy at baseline and change in functional
status over time (2 years)

4. To identify potential confounders of the relationship between polypharmacy and
functional status
a) To assess the role of chronic conditions in the relationship between polypharmacy
and functional status
b) To identify potential confounders or modifiers of the relationship between
polypharmacy and functional status

10

Chapter 2 Literature Review

2.1 Literature Review
This chapter is an examination of the literature on the relationship between polypharmacy
and functional status. Both functional dependency and medication problems are major concerns
among the older adult population. A decline in functional status may lead to an increase in health
system utilization and mortality, and is a major cause of functional dependency and
institutionalization (Fried & Guralnik 1997). Functional decline is usually a gradual process
resulting from aging and chronic conditions, which eventually affect the patient’s physical
abilities, although sometimes an acute event such as a stroke or a fracture could trigger a sudden
functional decline. The prognosis of functional decline depends on many factors such as a
patient’s age, gender, education, physical activity, cognitive status, and social support (Fried &
Guralnik 1997). It is important to mention that functional decline can sometimes be slowed or
reversed by rehabilitation and managing disability risk factors like polypharmacy (for example:
de-prescribing) and depression (Lin et al. 2012; Wehling et al. 2016; Thillainadesan et al. 2018).
Thus, if good care and early intervention were available, this may provide functional stability or
delayed decline. Older adults utilize a high number of medications, both prescription and
nonprescription. However, the consequences of multiple prescription medication use on
community-dwelling older adults are not well studied (Magaziner et al. 1989; Lau et al. 2011).
11

Based on a systematic review of the literature, I examined seven published papers that
discuss the relation between polypharmacy or PIM and functional status, The article were
selected based on the following inclusion criteria:
1-Observational cross-sectional and longitudinal studies
2-Older adults included in the study
3-Participants were community-dwelling
4-Study published in the English language
and the following exclusion criteria:
1-Restricted to specific drug categories and their relationship to functional decline
I used the following databases: PUBMED, CINAHL, and GOOGLE SCHOLAR. My
search strategy combined multiple search terms and MeSH terms to cover articles including the
following search terms: “functional status” OR “functional limitation” OR “functional decline”
OR “activity of daily living” OR “mobility” AND “polypharmacy” OR “multiple medications”
OR “Perception” OR “ADL” OR “IADL”, and filter: from 01/2011 to 01/2018, because there
was a review article published in 2011 that reviewed literature published through December
2010. I included the articles identified in this published literature review in my search. My
search resulted in 350 articles. I excluded 71 articles as not relevant to the topic based on the
title, and I reviewed the abstracts of 279 articles. I excluded 242 articles because they did not
meet my inclusion criteria, and fully reviewed 37 articles. Of those 37 articles, I excluded 29
articles that did not address the association between polypharmacy or PIM with functional status.
One additional article was excluded because it was conducted in a hospital setting, leaving seven
papers for critical review. Four of the seven papers selected were previously gathered in a
narrative review (Peron et al. 2011).
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I will first review the papers assessing polypharmacy and its relationship to functional
status (Table 2.1) followed by the papers discussing PIM and its relationship to functional status
(Table 2.2). The first paper by Magaziner et al. (1989) examined the relationship between
polypharmacy (number of prescribed medications) and OTC use in community-dwelling older
women, and the change in cognition, activities of daily living, and instrumental activities of daily
living. This study was a longitudinal study over one year. It looked at white women in the
Baltimore area age 65 and older (N= 609). This study examined self-reported ADL and IADL of
each participant, and controlled for age, education, and number and severity of chronic
conditions. For the analysis, they used a regression model with the function status scores after
one year as the outcome variable and number of prescribed medications at baseline as the
predictor variable, while controlling for the baseline variables. This study found no association
between the number of prescribed medications and change in cognitive function. The number of
prescribed medications increased the risk of decline in ADL, IADL, and depression. The OTC
medication use was associated with decline in ADL only (J. Magaziner et al. 1989). However,
this study had a significant generalizability limitation because only white females from the
Baltimore area were included. Also, they did not look at each chronic condition individually.
Moreover, they excluded patients who died or who entered institutions during follow up and this
may attenuate their observation.
The second study looked at the association between polypharmacy (6-9 medications) and
excessive polypharmacy (≥10 medications) with functional, nutritional, and cognitive status.
This study was conducted in Finland with a total sample size of (N=294) community-dwelling
older adults aged at least 75 years and followed for three years. Polypharmacy in this study
included all medication taken regularly including OTC and vitamins. Functional status was
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measured by IADL. They controlled for age, sociodemographics, self-reported health, and
comorbidity as measured by the functional comorbidity index score. It was found that both
polypharmacy and excessive polypharmacy were associated with a decline in IADL. Change in
functional status over a three-year period cannot be predicted by polypharmacy. This study had a
small sample size and their results cannot be widely generalized. However, despite the small
sample size, the association was strong. Moreover, they did not control for each chronic
condition individually (Jyrkkä et al. 2011a).

The third study was performed to evaluate the relationship between polypharmacy (≥5
prescribed medications) and functional decline among community-dwelling older adults with
dementia. They also wanted to evaluate whether PIMs (high risk drugs as defined by the 2003
Beers criteria) could modify this relationship. This study analyzed data from the National
Alzheimer’s Coordinating Center (NACC), where community-dwelling adults with dementia
aged 65 years and older (N=1,994) were included. Polypharmacy was defined as the use of ≥5
prescribed medications and they excluded patients with no prescription medication. The
functional status was measured by both ADL and IADL. They controlled for age, race, and
number of comorbid conditions from this list: hypertension, diabetes, hypercholesterolemia,
thyroid disease, urinary/bowel incontinence, heart disease, and cerebrovascular disease. They
found that participants with dementia and polypharmacy are more likely to have lower functional
status. PIMs did not modify this relationship (Lau et al. 2011). The limitation of this study was
that they did not account for OTC medications. The dataset used in this study did not have
random sampling and thus its results cannot be nationally representative. Moreover, they only
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controlled for the number of chronic conditions and they did not look at the effect of each
condition on the relationship individually.
The aim of the fourth study was to evaluate the association between three types of
potentially suboptimal prescribing of medications: 1) drugs-to-avoid in the 1997 Beer’s list, 2)
drug-drug interactions, and 3) polypharmacy defined as ≥ 5 medications (prescription and
OTC), with a latent variable representing a timed performance measure of functional status, the
short physical performance battery (SPPB). The SPPB can be used to measure functional status
by evaluating a person’s ability to perform three tasks: a balance score, a timed 3-meter walk,
and a repeated sitting to standing up from a chair. This study used the Hispanic Established
Populations for Epidemiologic Studies of the Elderly (HEPESE) of Mexican-American
community-dwelling older adults. They followed participants for seven years and the sample size
was (N=1,682). They controlled for sociodemographic characteristics along with smoking,
weight, self-reported health conditions, cognition status, and specific chronic conditions
(diabetes, hypertension, cancer, arthritis, stroke, and cardiovascular conditions) recognized by
the National Center for Health Statistics as the leading cause of mortality and disability in the
US. This study concluded that only polypharmacy defined as ≥5 medications was associated with
a change in SPPB. One of the strengths of this study was that it looked at the relationship
between specific chronic conditions and functional status and it reported a relationship between
diabetes, arthritis, and stroke with functional decline. However, this study is only generalizable
among community-dwelling Mexican-American older adults. Also, their high dropout rate and
death rate in this study population may attenuate the results (Pugh et al. 2008).
The fifth study was a cross-sectional study, performed to identify factors associated with
disability specially polypharmacy (≥5 medications) among community-dwelling older adults in
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the Irish longitudinal study. They also wanted to identify other factors that could be associated
with functional decline. The study participants were (N=3,499). Polypharmacy was defined as
the use of ≥5 medications. The functional status was measured by ADL, IADL and combined
ADL/IADL. They controlled for twenty-five possible confounders. They found that
polypharmacy was the third strongest factor associated with decline in ADL and IADL/IADL,
after age and pain. Polypharmacy was the sixth strongest factor associated with IADL decline.
(Connolly et al. 2017). The limitations of this study were the use of self-reported questionnaire
which could introduce source of bias. Also, the definition of polypharmacy was not clear and not
well-defined. They also had lots of missing data.
Table 2.1: Studies examining the relationship between polypharmacy and functional status
Author &
year

Study
population

Design

Polypharmacy
definition

Functional
Results &
status
conclusion
Measurement

Magaziner Communityet al. 1989 dwelling white
women in the
Baltimore area
age 65 and older
(N= 609)

Longitudinal
study over
one year

Self-reported
ADL,
IADL

Jyrkkä et
al. 2011

Communitydwelling older
adults aged at
least 75 years
(N=294)

Longitudinal
study for
three years

1-Number of
prescribed
medications taken
in last month
2-Number of
OTC taken last
month
1-Nonpolypharmacy
≤ 5medications*
2-Polypharmacy
6-9 medications*
3-Excessive
polypharmacy
≥10 medications*

Lau et al.
2011

Communitydwelling adults
with dementia

Longitudinal
for 4 years

1-Ppolypharmacy
≥5 Rx
2-PIMs (high risk
drugs as defined
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1-Decline in both
ADL and IADL
with prescription
medication usage
2-Decline in ADL
only with OTC
usage
Self-reported
1-Polypharmacy
IADL
and excessive
polypharmacy
were associated
with a decline in
IADL
2- Change in
functional status
over a three-year
period cannot be
predicted by
polypharmacy
Self-reported
1-Polypharmacy
ADL and
was associated
IADL (decline with functional
was defined as decline

aged 65 years and
older (N=1,994)

Pugh et al.
2008¥

Connolly
et al.
2017

Communitydwelling
MexicanAmerican older
adults aged 65
years and older
(N=1,682)
Communitydwelling Irish
longitudinal
survey of ageing
(N=3,499)

by the 2003 Beers
criteria) as a
modifier for the
relation

any decline in
ADL and/or
IADL)

Longitudinal
study for
seven years

Polypharmacy
defined as ≥5
medications
(prescription and
OTC)

The short
physical
performance
battery
(SPPB)

Crosssectional

Polypharmacy
defined as ≥5
medications

ADL, IADL
and
ADL/IADL

2-Participants
with dementia and
polypharmacy had
a lower functional
status
3-PIMs did not
modify the
relation
1-Polypharmacy
showed an
association with
functional decline

1-Polypharmacy
was the third
strongest factor
associated with
ADL and
IADL/ADL
decline, after age
and pain
2-Polypharmacy
was the sixth
strongest factor
associated with
IADL decline.

Rx: prescription medication only, * All medications taken regularly (including prescribed, OTC,
and vitamins)
¥ This study assessed both polypharmacy and PIM
Hanlon et al. (2002) discussed the relationship between PIMs and functional decline. The
definition of PIM in this study was the use of drug-to-avoid in the1997 Beer’s list or dosage,
duplication, duration, drug-drug, or drug-disease interaction with eight medications classes
(digoxin, nonsteroidal anti-inflammatory medications, calcium channel blockers, antihistamines,
angiotensin converting enzyme inhibitors, benzodiazepines, antipsychotics, and antidepressants).
This study used the fourth wave of the Duke Established Populations for Epidemiologic Studies
of the Elderly (EPESE) and included community-dwelling older adults in North Carolina. The
sample size was (N=3,234) and the study was longitudinal for 3 years. This paper evaluated the
decline in the ADL, IADL, and the abbreviated Rosow-Breslau scale, which measures the
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person’s ability to do heavy physical work around the house. They found no association between
the use of PIMs and mortality. There was an association between PIMs (drug-drug or drugdisease interaction) and decline in ADL. This study had several limitations including selfreported functional status measures and limited generalizability. Furthermore, the drugs-to-avoid
were only measured by looking at the classes of medications, and not the individual medications,
that the patient used. It is important for health care providers to note that even though a
medication may be on the Beers, it might be appropriate for the patient’s needs (Hanlon et al.
2002).
The last paper discussed the impact of PIMs (drug-drug and drug-disease interactions) on
functional status. This four-year longitudinal study used data from the Health, Aging and Body
Composition Study (Health ABC) and participants were community-dwelling older adults
Medicare recipients living in Pittsburgh, Pennsylvania, and Memphis, Tennessee (N=2,402).
Gait speed decline ≥0.1 m/s was used to measure functional status. They controlled for selfreported health, hospitalization in the last year, number of prescribed medications, number of
OTC medications, depression, self-reported coronary heart disease, peripheral artery disease,
diabetes, osteoarthritis, osteoporosis, pulmonary disease, and stroke. Results showed that drug
interactions may increase the likelihood of gait speed decline among older adults.
Generalizability and selection bias are the primary limitations in this study (Naples et al. 2016).
Table 2.2: Studies examining the relationship between PIMs and functional status
Author
& year

Study
population

Design

PIMs definition

Functional
status
Measureme
nt

Results &
conclusion

Hanlon
et al.
2002

Communitydwelling older
adults aged 65
years and older

Longitudinal
study over
three years

1-drugs-to-avoid in
1997 Beer’s list
2-dosage
3-duplication

Selfreported
ADL,
IADL,

1- Decline in ADL
only with drugdrug, or drugdisease interaction
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in North
Carolina
(N=3,234)

Naples
et al.
2016

Communitydwelling older
adults aged 65
and older
(N=2,402).

Longitudinal
study over
four years

Pugh et
al.
2008¥

Communitydwelling
MexicanAmerican
older adults
aged 65 years
and older
(N=1,682)

Longitudinal
study for
seven years

4-duration
5-drug-drug or drugdisease interaction
with 8 medications
classes
PIMs: drug-drug and
drug-disease
interactions

RosowBreslau
scale

2- No association
between the use of
PIMs and
mortality

Gait speed
decline ≥0.1
m/s

1-Drugs-to-avoid in
1997 Beer’s list
2-Drug-drug
interactions

The short
physical
performance
battery
(SPPB)

Drug interactions
may increase the
likelihood of gait
speed decline
among older
adults
Drug to avoid and
drug-drug
interaction showed
no association
with decline in
SPPB

¥ This study assessed both polypharmacy and PIM

2.2 Gaps in the literature
The literature is sparse, but it suggests that there is an association between polypharmacy
and functional status, and that polypharmacy is one of the important risk factors not only for
functional decline but also for PIM use (Lau et al. 2010). Polypharmacy’s relationship with
functional status needs further study. There is not as much research done in this area (Jyrkkä et
al. 2011; Peron et al. 2011). Limitations in the studies reviewed in this chapter lead to some gaps
in the literature that need to be addressed. The generalizability of all the studies is limited, since
none of them used nationally representative datasets. Some of the studies used all medications
including prescription and nonprescription for the number of medications, while others studies
used only prescribed medications. An inconsistent definition of polypharmacy may lead to
conflicting results. Using self-reported measures of polypharmacy, functional status or
confounding variables can introduce bias such as information bias, which occurs when there is
an inaccurate measurement or misclassification of diseases or exposures. Information bias can be
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introduced by: 1) the instruments used to measure the exposure or 2) the study participants, if a
participant cannot remember the information needed accurately (recall bias), having missing
data, or giving a socially desirable response or 3) investigators asking leading questions or
lacking proper training.
Moreover, the studies that used PIMs did not individualize the process for each patient’s
need to check whether medications on the drugs-to-avoid list might be appropriate for that
patient, and thus results may be inaccurate. Another limitation is that each study had different
potential confounders that were adjusted for. Most of the studies controlled for the number of
chronic conditions and only one study looked at each chronic condition individually. Since
polypharmacy is associated with chronic conditions, then it is important to look not only at the
number of chronic conditions but also at each chronic condition. Understanding the relationship
between each chronic condition, polypharmacy and functional decline will enrich the literature
and help us to better understand these relationships. In conclusion, polypharmacy, defined as the
use of a certain number of medications, is an important risk factor for functional decline and
increases the risk of PIMs, adverse drug reactions. Polypharmacy needs more attention and we
need to look at the potential confounders of the relationship. In my study, I will use a nationally
representative dataset to understand the relationship between polypharmacy and functional status
among community-dwelling older adults in the US. I will also look at each chronic condition as a
potential confounder to better understand the relationship between polypharmacy and functional
decline.
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Chapter 3 Methodology

In Chapter 3, the methodology employed to address the specific aims posed in Chapter 1
will be discussed. Data source, study design, study population and study variables will be
elaborated. This study was reviewed and approved as exempt by Virginia Commonwealth
University Institutional Review Board (IRB) (ID:HM20011568).
3.1 Data source
The Health and Retirement Study (HRS) is a nationally representative health survey of
older adults in the United States. HRS follows an open cohort of adults age 50 years or older in
the United States, with repeat surveys and new additions to the cohort every two years. This is a
uniquely rich, longitudinal data set for the community of scientific and policy researchers who
study the health, economics, and demography of aging. The National Institute on Aging sponsors
the HRS and the Institute for Social Research at the University of Michigan collects the data.
The main HRS longitudinal survey is publicly available, and supplementary surveys with
potentially sensitive data are available with an application for restricted use data. HRS data
collection is conducted by an in-person interview (face-to-face) for a random half of the sample
followed by a telephone interview for the next survey which takes place after two years. The
next cycle goes back to the in-person interview and so on. A by-proxy interview is conducted if
the person is unable to answer for himself or herself. Self-reported questionnaires are used for
supplementary surveys.
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3.2 Study design
This study is a retrospective longitudinal study that follows the same cohort of people in
HRS biannually from 2004-2009. The first aim was to determine the prevalence of prescription
medication usage and common response to adverse effects among community-dwelling US older
adults. Data used in this study were collected by HRS biannually in 2004, 2006, and 2008 which
corresponds to waves seven, eight and nine, and the supplementary drug survey data collected in
2005, 2007, 2009 which correspond to Prescription Drug Survey (PDS)05, PDS07, and the
Health and Well-Being Study (HWB)09. The HRS data is publicly available. The supplementary
drug survey was collected by mail, and a special request through the HRS website was made to
obtain these datasets.
3.3 Data merge
All waves were merged and cleaned, and all long data (PDS05, PDS07, HWB09) were
converted to wide data to merge them with wide HRS waves (7, 8, 9). HRS waves used in this
study were cleaned and compiled by RAND Corporation. Common participant identifiers (PN,
HHID) were used to merges the files together. All variables in PDS05, PDS07, and HWB09
were given a prefix, except for PN and HHID, to be able to merge them without overlapping
since some variables have common names. After that, cleaning the dataset and recoding the
variables needed for this study was performed. Details regarding merged files and recoding are
available in the Appendix (Tables A, B, and C).
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3.4 Study population
This study used data from HRS waves 7, 8 and 9, which were collected in 2004, 2006 and
2008, and from the supplementary surveys: 2005 and 2007 PDS, and 2009 HWB. The
supplementary surveys provide data about medications. The PDS includes a subsample of the
participants in the HRS; it is composed of two surveys, one of which was done in 2005 and the
other in 2007. It is considered a supplementary survey designed to capture the change in
prescription medication utilization before the implementation of Medicare part D and afterward.
This survey is intended to capture prescription medication use, coverage, and satisfaction. The
HWB (2009) is a continuation of the PDS survey to track and capture changes in prescription
drug utilization and registration in Medicare Part D. The HWB followed the same people in PDS
plus an additional 22% random sample from HRS.
This study included respondents who were:
1- Adults aged 65 years and older
2- Community-dwelling at baseline
Respondents were excluded if they were:
1- Missing data about their functional status, number of medications, or necessary model
covariates.
2- Not followed in waves 7, 8, and 9
3- Living in a nursing home at baseline
4- Interviewed by proxy at baseline
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After merging all files, all participants who had medication information and functional status
information totaled 2259 participants. Inclusion and exclusion criteria were applied:
removing participants younger than 65 years at baseline (593 were deleted) => 1666,
removing participants interviewed by proxy at baseline (105 were deleted) =>1561,
removing participants living in nursing homes at baseline (3 were deleted) => 1558, and
removing participants who were alive but did not respond (13 were deleted) => 1545, resulting
in 1545 participants included in the analysis.
3.5 Study variables
3.5.1 Main exposure variable
The primary exposure in this study was polypharmacy, defined as the number of
prescribed medications used regularly. This is the most commonly used definition in the
literature (Masnoon et al. 2017), facilitating comparison of our results with other published
studies. HRS participants were asked if they were taking prescribed medications last year and if
yes, then how many prescribed medications do they take regularly? Evidence of polypharmacy
was also identified in the PDS and HWB datasets. Polypharmacy was categorized as present or
absent using a definition that is commonly used in other studies (Pugh et al. 2008; Jyrkkä et al.
2011; Lau et al. 2011):
1-non-polypharmacy: using <5 prescribed medications
2-polypharmacy: using ≥5 prescribed medications
In the sensitivity analysis, different cut-offs were assessed as well:
1-non-polypharmacy: using <5 prescribed medications
2-polypharmacy: using 5-9 prescribed medications
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3-excessive polypharmacy: using 10 or more prescribed medications
3.5.2 PDS and HWB variables:
From the medication drug survey data, the following information about prescribed medications
were merged, cleaned, and coded: drug names, duration of medication use, side effects, response
to side effects and unwanted drug reactions, and source of prescribed medications. Prescription
medication coverage at baseline was categorized as: some by self and rest by insurance, small
discounts, full price, pay nothing, and other. However, at the end of the study the categories were
collapsed into having a prescription medication coverage (yes, no).
3.5.3 Main outcome
The outcome examined in this study was functional status, which was assessed with two
widely used and well-validated measures: activities of daily living (ADL) and instrumental
activities of daily living (IADL). ADL in this data set include five basic activities: bathing,
dressing, walking across a room, getting in or out of bed, and eating. IADL include food
preparation, shopping, medication administration, using the telephone and managing money.
Counts were used to measure the number of activities in which participants experience
impairments, with a possible range of 0-5 for ADL and 0-5 for IADL, with lower scores
indicating better function and higher scores indicating greater disability (Germain et al. 2016).
Each score was dichotomized into a yes/no variable to represent whether participants experience
difficulty performing tasks in that category (score ≥1) and those able to function without
difficulties (score=0).
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3.5.4 HRS variables
All the variables were cleaned, and the missing observations were recoded to (.) for
analysis purposes. Demographics were age, gender, race, ethnicity, years of education, marital
status, and number of residents living in the same house including participant and spouse.
Household income/wealth, which is the sum of all income in a household, was re-categorized
according to the four quartiles (low, mid-low, mid-high, and high). Other variables used were
self-reported health, smoking, and alcohol drinking. Obesity was measured by the body mass
index (BMI), which measures the body fat by calculating the ratio of weight to height. If BMI ≥
30 kg/m2, the participant was considered obese. The amount of monthly light physical exercise
was also used in our study. For health insurance, participants were asked whether they are
covered by any government health insurance program. Other variables were proxy interviewed
participants, and institutionalized participants in a nursing home or a health care facility. (See
Table 3.1).
Table 3.1 HRS variables considered in the study
The confounder

The category

Age

65-74 years
≥75years

Gender

Male
Female

Race and ethnicity

Non-Hispanic white
Non-Hispanic African American
Others
Hispanic

Years of education

0-6 years
7-12 years
>13 years
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Marital status

Married
Divorced
Widowed
Never married

Number of residents living in the same house Alone
including participant and spouse
Two persons
More than two
Household income (wealth)
Low quartile <$16.000
Mid-low quartile $16,000-$29,999.9
Mid-high quartile $30,000-$54,999.9
High quartile ≥ $55,000
Self-reported health

Smoking

Alcohol drinking
Obesity
Light exercise

Governmental health insurance
Proxy interview
Institutionalization

Excellent
Very good
Good
Fair
Poor
Current smoker
Former smoker
Never smoker
Yes
No
Obese
Not obese
Every day
More than once per week
Once per week
One to three times per month
Never
Yes
No
Yes
No
Yes
No
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3.5.5 Health conditions
The number of chronic conditions is a count variable for how many chronic conditions
each participant has ever been told that he/she had out of the eight following chronic conditions:
1) high blood pressure or hypertension, 2) high blood sugar or diabetes, 3) heart diseases
including heart attack, angina, coronary heart conditions, angina, or congestive heart failure, 4)
cancer or malignancy of any kind except skin cancer, 5) stroke or transient ischemic attack, 6)
chronic lung disease, chronic bronchitis or emphysema except asthma, 7) psychiatric problems,
and 8) arthritis or rheumatism. Each of the chronic conditions were coded as yes/no. Depression
was measured using the Center for Epidemiologic Studies Depression (CESD) scale score. This
score is the sum of 1) the "negative" indicators which include a yes answer to the following:
depression, felt sad, lonely, everything was an effort, restless sleep, and could not get going and
2) the "positive" indictors which includes a no answer to the following: feeling happy, and
enjoying life. A score of four or more was considered depression. For cognitive impairment, I
used the total cognition score, which is the sum of the total word recall and mental status
summary scores, resulting in a score range of 0-35. As in prior HRS studies, 10 or lower in
cognitive scores was considered impairment.
Three common terms will be used in the upcoming chapters:
1) Baseline (2004): data collected in the beginning of the study and files used were HRS
2004 and PDS 2005
2) Midline (2006): data collected in the middle of the study and files used were HRS 2006
and PDS 2007
3) Endline (2008): data collected in the end of the study and files used were HRS 2008 and
HWB 2009
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3.6 Statistical analyses
Aim 1: To determine the prevalence of prescription medication usage and adverse
effects among community-dwelling US older adults
Descriptive statistics were reported for the study variables. For continuous variables (age,
years of education, number of people in the same house, and total household income) normality
was assessed to choose between parametric and non-parametric tests. Normality was assessed by
looking at the histogram and the Q_Q plot. Moreover, Goodness-of-fit tests (KolmogorovSmirnov, Cramer-von Mises, and Anderson-Darling) were also used to assess normality and pvalue <0.05 suggests non-normality. For categorical variables, PROC SURVEY was used to
report unweighted N and PROC SURVEYFREQ procedure was used to report the weighted
percent in each category.
Aim 2: To assess the cross-sectional relationship between polypharmacy and functional
status using a large nationally-representative dataset
After re-coding baseline, midline, and endline characteristics, Chi-square was performed
to report un-weighted N followed by PROC SURVEYFREQ to report weighted % and Rao-Scott
Chi-Square test to report the p-value. These tests were done between each variable of interest and
participants with or without ADL impairment at baseline. A bivariate analysis between each one
of our study variables and the main outcomes (ADL and IADL) at both baseline and end line was
done using PROC SURVEYLOGISTIC procedure, the unadjusted odds ratio (OR) along with
the 95% CI and p-value were recorded. Logistic regression was chosen because the main
outcome variables (ADL and IADL) were dichotomous. The variables that showed an
association with the outcomes (ADL and IADL) were then tested by building a model and using
the manual backward elimination method (p=0.1). In this method, the least significant variable
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was dropped, except the main predictor, until all remaining variables had p-value of 0.1 or less.
This method allows us to keep the important variables in the model even if it was not significant.
A collinearity check was not performed because all variables were categorical. These regressions
analyses were weighted by the HRS sampling weights and accounted for the complex sampling
by using PROC SURVEYLOGISTIC and PROC SURVEYFREQ. The subsample groups in the
PDS and HWB files were accounted for by using appropriate HRS sampling weights (An &
Lu,2016). Interactions were added to the model for self-reported health and polypharmacy, and
self-reported health and each of the eight chronic conditions, but none were significant.
Aim 3: To assess the longitudinal relationship between polypharmacy and functional status
using a large nationally-representative dataset and Aim 4: To identify potential
confounders of the relationship between polypharmacy and functional status
For longitudinal models, the adjustment was performed for the baseline variables, and the
backward elimination method was also used. Polypharmacy status was kept in the model even if
it was not significant. Moreover, multiple interactions were added to the model, but none was
significant. Model assumptions and diagnostics were checked by PROC LOGISTIC procedure
and the LACKFIT option to perform a Hosmer and Lemeshow Goodness-of-Fit Test. A nonsignificant p-value rules out a gross lack of fit. Influential points were also checked to detect any
unusual observations.
3.7 Missing data
Dealing with missing data in SAS starts with cleaning the data:
1) checking for missing data for each variable we want to use,
2) re-coding the missing for answer like (refusal, no response, unknown, etc.), and
3) rechecking if variables are coded correctly, and

30

4) making a new data set with the variables of interest to ensure that no unneeded
variables were included, especially in a large data set like HRS, which may increase the amount
of missing information. Listwise deletion or complete case analysis was used in our study.
Listwise deletion is a convenient simple method and it is the most commonly used method in
research. Because of the large sample size available in this study, listwise deletion can be used
without substantial loss of statistical power (Dong & Peng 2013). Moreover, the missing data is
acceptable when it is less than 10% of the sample, which is the case in our study (Dong & Peng
2013). HRS is a large survey with no intervention, so drop out because of an intervention
resulting in not at random (MNAR) missing data is unlikely. The missing data in this study is
most likely missing completely at random (MCAR) which means the missed information is not
related to the study, or missing at random (MAR) which means that the missed information can
be explained, and there is a pattern but the reason is not related to the primary dependent
variable.
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Chapter 4 Results

Aim 1: Descriptive results
A total of 1558 HRS participants met our inclusion and exclusion criteria in 2004 and
were followed up until 2008. However, 13 of these participants were lost to follow up but were
still alive at the end of the study period so they were excluded, leaving 1545 participants in our
study. Table 4.1 shows the baseline and endline characteristics of the study participants.
Regarding our main study predictor polypharmacy, 64.1 % were taking less than five prescribed
medications, and 35.9% were considered having polypharmacy and taking five or more
prescribed medications at baseline. For self-reported health, we have quite good perceived
health, as most reported very good to good health status. Regarding our primary outcome, ADL
and IADL, 11.5% and 9.5% reported difficulties in those two outcomes at baseline. Also, the
most common chronic health conditions were hypertension (55.7%) and arthritis (60.4%).
Looking at the same participants after four years, 19.4% have shifted their age category from 6474 years to 75+ years. For polypharmacy, the percentage of individuals taking less than five
prescribed medications decreased and the percentage meeting the criteria for polypharmacy
increased over 4 years, indicating that drug burden increased over time in these participants.
Participants reported difficulties in ADL (16.2%) and IADL (13.8%) at the endline, indicating a
decline in functional status over time in this population. The percentage of individuals suffering
from hypertension and arthritis also increased over time.
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Table 4.1: Baseline and endline characteristics of the study population 2004 -2008
Variables

Age (years)
65-74
≥75
Gender
Male
Female
Race and Ethnicity
Non-Hispanic white
Non-Hispanic African American
Others
Hispanic
Marital status
Married
Divorced
Widowed
Never married
Polypharmacy
0-4 medications
≥5 medications
ADL
No difficulty
Difficulty
IADL
No difficulty
Difficulty
Self-reported health
Excellent
Very good
Good
Fair
Poor
# of chronic condition
0
1
2
3
4
5
6
7

2004
Unweighted n
(weighted %)

2008
Unweighted n
(weighted %)

1159 (70.8%)
386 (29.2%)

844 (51.4%)
701(48.6%)

628 (41.0%)
917 (59.0%)

628 (40.8%)
917 (59.2%)

1219 (86.2%)
189 (6.8%)
26 (1.9%)
111 (5.1%)

1205 (86.1%)
186 (6.5%)
26 (1.9%)
109 (5.4%)

984 (63.8%)
137 (7.9%)
389 (25.9%)
35 (2.4%)

884 (56.2%)
137 (7.9%)
490 (33.5%)
34 (2.4%)

986 (64.1%)
559 (35.9%)

897 (59.3%)
647 (40.7%)

1366 (88.5%)
179 (11.5%)

1284 (83.8%)
261 (16.2%)

1403 (90.9%)
142 (9.1%)

1326 (86.2%)
219 (13.8%)

168 (10.7%)
476 (32.1%)
524 (34.7%)
290 (17.6%)
86 (4.8%)

115 (7.4%)
460 (31.7%)
540 (35.8%)
316 (18.4%)
114 (6.7%)

182 (12.4%)
409 (27.0%)
456 (29.7%)
313 (19.5%)
129 (7.9%)
39 (2.4%)
15 (1.0%)
2 (0.1%)

105 (7.3%)
300 (20.1%)
463 (30.1%)
367 (24.3%)
184 (11.2%)
81 (4.1%)
29 (1.8%)
7 (0.4%)
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Hypertension
b
No
662 (44.3%)
521 (35.9%)
yes
881 (55.7%)
1021 (64.1%)
Diabetes
a
No
1281 (84.3%)
1217 (80.1%)
Yes
261 (15.7%)
326 (19.9%)
Heart conditions
No
1168 (75.8%)
1063 (69.5%)
Yes
377 (24.2%)
482 (30.5%)
Lung conditions
a
No
1433 (93.2%)
1367 (89.4%)
Yes
111 (6.8%)
167 (10.6%)
Cancer
c
No
1291 (83.2%)
1224 (79.3%)
Yes
246 (16.8%)
311 (20.7%)
Stroke
b
No
1143 (93.5%)
1377 (89.1%)
Yes
102 (6.5%)
165 (10.9%)
Psychiatric conditions
a
No
1396 (90.8%)
1350 (88.1%)
Yes
148 (9.2%)
191 (11.9%)
Arthritis
a
No
595 (39.6%)
488 (32.6%)
Yes
949 (60.4%)
1055 (67.4%)
Total sample size N= 1545, a= 2 missing, b= 3 missing, c= 10 missing, PROC SURVEY
was used for this analysis.

Aim 1-A) To determine the prevalence of prescribed medication usage among communitydwelling US older adults
In our study, 9.8% did not take any prescribed medications, 54.3 % were taking 1-4
prescribed medications, and 35.9% were taking five or more prescribed medications at baseline.
The most commonly prescribed medications at baseline are presented in Table 4.2. Atorvastatin
was the most commonly used prescribed medication in our study population in 2004.
Atorvastatin is an HMG CoA reductase inhibitor, which helps lower blood cholesterol levels, and
it helps reduce the risk of cardiovascular events. The second most common medication was
levothyroxine, used to treat hypothyroidism. Metoprolol was the third most commonly used
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medication. It is a beta-blocker used to control hypertension, manage patients after myocardial
infarction, and to treat heart failure, tachycardia, and angina.
Table 4.2: The most commonly prescribed medications at baseline
Drug name

N (%)

Pharmacological category

Atorvastatin

234 (15.1%) HMG CoA reductase inhibitor (lowers cholesterol)

Levothyroxine

213 (13.8%) Synthetic thyroxine to treat hypothyroidism

Metoprolol

201 (13.0%) Beta-blocker for angina and hypertension

Lisinopril

183 (11.8%) ACE inhibitor for hypertension and heart failure

Atenolol

142 (9.2%) Beta-blocker for angina and hypertension

Hydrochlorothiazide

141 (9.1%) Diuretic for hypertension

Furosemide

130 (8.4%) Potent loop diuretic

Simvastatin

126 (8.2%) HMG CoA reductase inhibitor (lowers cholesterol)

Amlodipine

124 (8.0%) Calcium channel blocker for angina and
hypertension and kidney problems

Metformin

124 (8.0%) Oral antidiabetic agent that helps control blood
sugar levels

Warfarin

59 (3.8%) Oral anticoagulant

Aim 1-B) To assess the access to prescribed medications among US older adults including
pharmacies, prescription insurance and source of payment
The most common source for filling prescriptions in this community-dwelling older adult
population was drug store chains (29.2%), followed by mail order (21.7%) and independent
pharmacies (21.5%). Only 6.3% used clinic and hospital pharmacies. Filling prescribed
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medications over the internet was the least used method (1%) at the time that this data was
collected. Table 4.3 displays the sources were prescribed medications were obtained by
participants in the HRS. The participants were allowed to choose more than one source for filling
their prescribed medications. In Table 4.4 we can see the source of the prescription insurance.
36.7% had employment-based drug insurance. 19.4% and 14.7% had Medicare HMO and
Medicaid prescription insurance. The payment sources for prescribed medications among HRS
participants is presented in Figure 4.1.
Table 4.3: The source for obtaining prescribed medications from most common to least
common source
Source of prescribed medications
Yes n (%)
No n (%)
Drug store chain
Mail order
Independent pharmacy
Supermarket
Department store chain
Others
Free samples
Veterans' Administration pharmacy
Clinics or hospital
Internet
Total n = 1404; missing =141

410 (29.2%)
305 (21.7%)
302 (21.5%)
208 (14.8%)
170 (12.1%)
136 (9.7%)
130 (9.3%)
103 (7.3%)
89 (6.3%)
12 (0.9%)
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994 (70.8%)
1099 (78.3%)
1101 (78.5%)
1196 (85.2%)
1234 (87.9%)
1268 (90.3%)
1274 (90.7%)
1301 (92.7%)
1315 (93.7%)
1392 (99.1%)

Table 4.4: The source of prescribed medications insurance
Source of prescription insurance

Yes n (%)

No n (%)

Employment insurance

411(36.7%)

708(63.3%)

Medicare HMO

217(19.4%)

902(80.6%)

Medicaid

165(14.7%)

954(85.3%)

Purchase from insurance

94(8.4%)

1025(91.6%)

Veterans' Administration pharmacy

92(8.2%)

1027(91.8%)

State pharmacy assistance

49(4.4%)

1070(95.6%)

207 (18.5%)

912(81.5%)

Others
Total n =1119; missing = 426

I don't pay
anything
8%

Others
5%

I pay full price
for all
medications
19%

I pay some of
the price and
insurance pays
the rest
55%

I get a small
discount off
13%

Figure 4.1: Prescription coverage and payment
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Aim 1 -C) To determine the prevalence of self-reported side effects and unwanted
reactions, and to understand the consequences of adverse drug reactions (e.g. stopping or
cutting down mediations, visiting the doctor’s office, admission to the hospital or the
emergency room)
This analysis investigates self-reported side effects, adverse reactions, and other
medication-related problems in community-dwelling US older adults. HRS participants were
asked if they had any side effects, unwanted reactions, or other health problems from
medications in past year. 1060 participants responded “no,” 246 responded “yes” and 239 did not
respond. Participants were then asked additional questions about the most severe unwanted
reactions and their responses are summarized in Table 4.5.
Table 4.5: Self-reported side effects, unwanted reactions, and the action taken in response
to this reaction
Questions asked
Yes
No
1-Cut down or stop taking the drug on your own a

106

98

2-Talk to a doctor about this reaction b

206

20

3-Visit a doctor's office or emergency room because of this reaction c

67

142

4-Doctor cut down or stopped the medication because of this reaction d

171

54

5-Take another medication or treatment to treat this reaction e

78

143

6-Admitted to a hospital overnight because of this reaction f

25

192

This table reports data for those who responded yes, a= 42 missing, b= 20 missing, c= 37
missing, d= 21 missing, e= 25 missing, f= 29 missing

In Table 4.5, we can see that participants called the doctor if they had a severe drug
reaction. Their doctors may cut down the medication or stop it, but most of the participants did
not need another medicine to treat the reaction or to be admitted to the hospital.
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Aim 2-To assess the cross-sectional relationship between polypharmacy and functional
status using a large nationally-representative dataset
2-A) Cross-sectional study looking at the association between ADL and polypharmacy at
baseline (2004)
In the contingency Table 4.6, demographic and functional status-related factors are
grouped by ADL difficulty and no difficulty. There was a significant difference in participants
with and without ADL difficulties in the following factors: polypharmacy, marital status, number
of people living in the same home, education, total household income, self-reported health status,
number of chronic conditions, hypertension, diabetes, heart conditions, stroke, arthritis,
psychiatric conditions, depression, drinking alcohol, obesity, and light exercise. The nonsignificant variables where: age, gender, race, having a lung condition, having cancer, smoking
status, cognitive status, and having government health insurance. A detailed bivariate analysis
was then conducted to examine the demographic and functional status-related factors, with each
outcome (ADL and IADL) in both baseline and endline.

Table 4.6: Demographic and functional status-related factors, grouped by ADL no
difficulty and difficulty
Variable
2004
P-value c
ADL no difficulty
ADL difficulty
a
b
a
n (weighted %) n (weighted %)b
Age (years)
0.2925
65-74
1035 (71.4%)
124 (66.7%)
≥75
331 (28.6%)
55 (33.3%)
Gender
0.1009
Male
569 (41.9%)
59 (34.2%)
Female
797 (58.1%)
120 (65.8%)
Race
0.1855
White
1166 (90.6%)
142 (87.2%)
African American
158 (6.4%)
32 (10.0%)
Others
42 (3.0%)
5 (2.8%)
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Marital status
Married
Divorced
Widowed
Never married
Education
0-6 years
7-12 years
>13 years
# of people living in
same house
Alone
2 persons
More than 2
Wealth
Lowest quartile
Mid-low quartile
Mid-high quartile
Highest quartile
Polypharmacy
0-4 medications
≥5 medications
Self-reported health
Excellent
Very good
Good
Fair
Poor
# chronic conditions
0
1
2
3
4
5
6-7
Hypertension
No
Yes
Diabetes
No
Yes
Heart conditions
No
Yes

0.0025
897 (65.6%)
115 (7.5%)
323 (24.4%)
31 (2.5%)

87 (50.1%)
22 (10.6%)
66 (37.3%)
4 (2.0%)

59 (3.2%)
766 (55.5%)
541 (41.2%)

19 (8.2%)
120 (67.5%)
40 (24.2%)

<0.0001

0.0300
344 (27.1%)
816 (58.3%)
206 (14.6%)

54 (32.8%)
89 (46.3%)
36 (20.9%)

283 (19.5%)
322 (23.0%)
382 (28.5%)
379 (29.0%)

82 (41.8%)
45 (24.8%)
30 (18.7%)
22 (14.7%)

1211 (65.2%)
689 (34.8%)

187 (55.5%)
146 (44.5%)

<0.0001

0.0053

<0.0001
164 (12.0%)
461 (35.1%)
473 (35.5%)
223 (14.6%)
44 (2.9%)

4 (1.8%)
15 (9.6%)
51 (28.6%)
67 (40.3%)
42 (19.8%)

175 (13.6%)
378 (28.3%)
406 (29.7%)
264 (18.4%)
104 1(7.1%)
26 (6.7%)
13 (1.0%)

7 (3.3%)
31 (17.0%)
50 (29.2%)
49 (27.6%)
25 (14.2%)
13 (6.7%)
4 (2.1%)

604 (45.7%)
760 (54.3%)

58 (33.3%)
121 (66.7%)

1155 (86.1%)
208 (13.9%)

126 (70.3%)
53 (29.7%)

<0.0001

0.0048

0.0001

0.0401
1046 (76.7%)
320 (23.3%)
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122 (69.1%)
57 (30.9%)

Lung conditions
0.9285
No
1269 (93.1%)
164 (93.4%)
yes
96 (6.9%)
15 (6.6%)
Cancer
0.0855
No
1141 (83.3%)
150 (82.1%)
Yes
219 (16.7%)
27 (17.9%)
Stroke
0.0052
No
1284 (94.3%)
159 (86.7%)
Yes
82 (5.7%)
20 (13.2%)
Psychiatric conditions
<0.0001
No
1252 (92.1%)
144 (81.2%)
Yes
113 (7.9%)
35 (18.8%)
Arthritis
0.0002
No
555 (41.8%)
40 (22.6%)
Yes
810 (58.2%)
139 (77.4%)
Cognitive impairment
0.1018
No
1349 (99.0%)
174 (97.8%)
Yes
17 (1.0%)
5 (2.2%)
Depression
<0.0001
No
1241 (91.4%)
125 (74.1%)
Yes
125 (8.6%)
54 (25.9%)
Governmental health
0.6633
plan
No
38 (2.5%)
3 (1.9%)
Yes
1326 (97.5%)
3176 (98.1%)
Smoker
0.6321
Current
124 (8.3%)
17 (10.4%)
Former
597 (44.6%)
83 (46.6%)
Never
632 (47.1%)
79 (43.1%)
Alcohol drinking
<0.0001
No
1032 (47.2%)
231 (63.8%)
Yes
868 (52.8%)
102 (36.2%)
Obesity
<0.0001
No
1041 (78.5%)
94 (56.9%)
Yes
313 (21.5%)
84 (43.1%)
Light exercise
<0.0001
Every day
92 (6.4%)
8 (4.3%)
>1 week
777 (58.6%)
80 (43.7%)
1 per week
346 (24.2%)
43 (24.6%)
1-3 per month
73 (5.3%)
12 (5.3%)
Never
77 (5.5%)
36 (22.2%)
a-unweighted n value; b-weighted column percent, PROC SURVEYFREQ to report weighted
column % and, c-Rao-Scott Chi-Square test
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Bivariate and multivariable analyses were performed to examine the association between
ADL and IADL with covariates that showed significance or prior knowledge of their importance
from the literature. Looking at the bivariate analysis between ADL and variables at baseline
(2004) without adjusting for other variables yielded several observations. Participants who were
taking five or more prescribed medications were 1.6 (95% CI = 1.181-2.213) times more likely
to have difficulties in ADL than participants who were taking less than five prescribed
medications. Also, females were 1.5 (95% CI = 1.044-2.019) times more likely to have
difficulties in ADL than males. The odds of having difficulties in ADL for divorced, widowed,
and never married participants were 2.0 (95% CI = 1.189-3.273), 2.1 (95% CI = 1.493-2.973),
and 1.3 (95% CI = 0.459-3.856) respectively, compared to married couples. Participants with 712 years of education were almost 50% (95% CI = 0.280-0.844) as likely to report difficulties in
ADL and participants with 13 years or more of education were nearly 23% (95% CI = 0.1250.422) as likely to report problems in ADL than participants with 6 years or less of education.
Participants who were living with at least one person were 70% (95% CI = 0.484-0.997) as likely
to have difficulty with ADL than participants who lived alone. For wealth and total household
income, participants who were in mid-low income, mid-high income, and highest income
quartiles were 50% (95% CI = 0.324-0.717), 27% (95% CI = 0.174-0.423), and 20% (95% CI =
0.122-0.329) as likely to report difficulties in ADL than participants in the lowest quartile. For
self-reported health, those who reported good, fair, or poor health status were 4.4 (95% CI =
1.572-12.417), 12.3 (95% CI = 4.403-34.40), and 39.1 (95% CI = 13.312-114.994) times more
likely to have difficulties in ADL than those reporting excellent health status. The number of
chronic conditions also increased the likelihood of having ADL difficulties. Having any of the
following chronic conditions: hypertension, diabetes, heart conditions, stroke, arthritis, and
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psychiatric conditions, would result in a higher likelihood of reporting challenges in ADL
compared to those who do not have these conditions as presented in Table 4.7. Also, depressed
participants were 4.3 (95% CI = 2.967-6.211) times more likely to report challenges with ADL
than non-depressed participants. Those who drink alcohol were 50% (95% CI = 0.386-0.740) as
likely to have difficulties in ADL than non-drinkers. Obese participants were almost 3.0 (95% CI
= 2.158-4.094) times more likely to report problems with ADL than non-obese participants.
Participants who never do light exercise were 5.4 (95% CI = 2.360-12.256) times more likely to
develop difficulties in ADL than participants who do light exercise daily. (See Table 4.7)
The association between ADL at baseline with age, race, ethnicity, having lung conditions,
cancer, having cognition impairment, having government health insurance, having prescription
drug coverage, and smoking were not significant.
Table 4.7: Bivariate associations between participants’ study variables and ADL at the
baseline (2004)
Predictor variable

Unadjusted
OR
1.617

95% CI

p-value

1.181-2.213

0.0027*

Age (ref=65-74 years)

1.387

0.987-1.950

0.0598

Gender (ref=male)

1.452

1.044-2.019

0.0267*

Race (ref=white)
African American
Others

1.663
0.978

1.095-2.526
0.381-2.511

0.0566

Ethnicity (ref=Hispanic)

1.644

0.977-2.767

0.0611

Marital status (ref=married)
Divorced
Widowed
Never married

1.972
2.107
1.330

1.189-3.273
1.493-2.973
0.459-3.856

Polypharmacy

0.0001*
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Education (ref=0-6 years)
7-12 years
>13 years

< 0.0001*
0.486
0.230

# of people living in the home
(ref=alone)
2 people
>2

0.0345*
0.695
1.114

Wealth (ref=lowest quartile)
Mid-low quartile
Mid-high quartile
Highest quartile
Self-reported health (ref=excellent)
Very good
Good
Fair
Poor
Number of chronic conditions
(ref=0)
1
2
3
4
5
6-7

0.280-0.844
0.125-0.422

0.484-0.997
0.706-1.756
< 0.0001*

0.482
0.271
0.200

0.324-0.717
0.174-0.423
0.122-0.329

1.334
4.420
12.316
39.125

0.436-4.076
1.572-12.417
4.403-34.40
13.312-114.994

< 0.0001*

< 0.0001*
2.050
3.079
4.640
6.010
12.500
7.692

0.886-4.747
1.396-6.925
2.055-10.479
2.551-14.381
4.567-34.216
1.991-29.717

Hypertension a

1.658

1.191-2.308

0.0027*

Diabetes a

2.336

1.641-3.325

< 0.0001*

Heart conditions a

1.527

1.089-2.142

0.0142*

Lung conditions a

1.209

0.685-2.134

0.5123

Cancer a

0.938

0.607-1.448

0.7721

Stroke a

1.970

1.176-3.299

0.0100*

Psychiatric conditions a

2.693

1.776-4.085

< 0.0001*

Arthritis a

2.381

1.648-3.440

< 0.0001*
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Cognitive impairment a

2.280

0.831-6.258

0.1095

Depression a

4.292

2.967-6.211

< 0.0001*

Government health insurance a

1.681

0.514-5.504

0.3905

Prescription drug coverage
(ref=some by self and rest by
insurance)
Discounts
Full price
Pay nothing
Other

0.3373
1.052
0.661
0.663
1.126

0.644-1.716
0.405-1.078
0.309-1.296
0.518-2.449

Smoking (ref=current)
Former
Never
Alcohol drinking a

0.8088
1.014
0.912
0.535

0.581-1.769
0.522-1.593
0.386-0.740

0.0002*

Obesity (ref=non-obese)

2.972

2.158-4.094

< 0.0001*

Light exercise (ref=every day)
>1 week
1 per week
1-3 per month
Never

1.184
1.429
1.890
5.378

0.555-2.527
0.649-3.164
0.734-4.868
2.360-12.256

Using Atorvastatin a

1.216

0.799-1.852

< 0.0001*

0.3613

* p-value < 0.05, indicates significant relationship, a= reference group is No

A multivariable logistic regression model was developed with the significant variables in
the bivariate analysis and ADL. A backward elimination method (p=0.1) was used, and the least
significant variables were removed one at a time until the model had only variables with a pvalue of 0.1 or less. Tables 4.8 and 4.9 display the variables remaining in the model. The results
of the final model for this cross-sectional analysis showed that polypharmacy, light exercise,
self-reported health, depression, and obesity were all significant predictors for reporting ADL
difficulties at baseline. Arthritis and psychiatric condition were in the final model because their
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p-value was < 0.1 but > 0.05 (p=0.0598 and p=0.0891). Participants with polypharmacy were 1.4
(95% CI = 1.047-1.971) times more likely to report ADL difficulties than participants with nonpolypharmacy after controlling for other confounders. Participants reporting good, fair, or poor
health status were 4.2 (95% CI = 1.199-14.399), 11.2 (95% CI = 3.336-37.507) and 18.6 (95%
CI = 5.194-66.773) times more likely to have ADL difficulties than participants with excellent
health status. Those who never exercise lightly are 2.9 (95% CI = 1.073-8.001) times more likely
to report ADL difficulties than those who exercise daily controlling for other confounders.
Depressed individuals were 1.8 (95% CI = 1.020-3.160) times more likely to report ADL
difficulties. Moreover, obese persons were 1.9 (95% CI =1.303-2.782) times more likely to
report ADL difficulties. The detailed results are presented in Tables 4.8 and 4.9. According to
the Goodness-of-Fit Test (p=0.9793), there was no gross lack of fit in this model.

Table 4.8: The predictor variables in the cross-sectional final model for ADL at baseline
Variables
p-value
Polypharmacy

0.0256

Self-reported health

< 0.0001

Light exercise

0.0170

Arthritis

0.0598

Depression

0.0428

Obesity

0.0013

Psychiatric conditions

0.0891
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Table 4.9: The adjusted odds ratio of the predictor variables in the cross-sectional final
model for ADL at baseline
Variables

Adjusted OR

Polypharmacy

95% CI

1.437

1.047 1.971

Very Good

1.620

0.458 5.728

Good

4.154

1.199 14.399

Fair

11.186

3.336 37.507

Poor

18.623

5.194 66.773

>1 per week

0.897

0.419 1.918

1 per week

0.898

0.370 2.179

1-3 per month

0.780

0.293 2.075

Never

2.930

1.073 8.001

Arthritis (ref= no)

1.602

0.980 2.620

Depression (ref= not depressed)

1.795

1.020 3.160

Obesity (ref= non-obese)

1.903

1.303 2.782

Psychiatric conditions (ref= no)

1.606

0.928 2.779

Self-reported health (ref=excellent)

Light exercise (ref= everyday)

Goodness-of-Fit Test p= 0.9793, N= 1529, 16 missing observations were
deleted
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Aim 2-B) Cross-sectional study looking at the association between ADL and polypharmacy
at endline (2008)
The bivariate analysis at endline (2008) between ADL and study variables without
adjusting for them showed the following observation: Participants who were taking five or more
prescription medications were 3.6 (95% CI = 2.723-4.803) times more likely to have difficulties
in ADL than participants who were taking less than five prescription medications. Also,
participants aged 75 years and older were 1.9 (95% CI = 1.426-2.445) times more likely to have
difficulties in ADL than participants aged 65-74 years. The odds of having difficulties in ADL
for widowed participants were 1.9 (95% CI = 1.470-2.594) compared to married couples,
however, divorced and never married couples did not show a significant association. Participants
with 7-12 years of education were almost 50% (95% CI = 0.302-0.838) as likely to report
difficulties in ADL, and participants with 13 years or more of education were nearly 33% (95%
CI = 0.195-0.571) as likely to report problems in ADL than participants with 6 years or less of
education. For wealth and total household income, participants who were in the mid-low income,
mid-high income, and highest income quartiles were 56% (95% CI = 0.412-0.831), 40% (95% CI
= 0.275-0.569), and 26% (95% CI = 0.174-0.395) as likely to report difficulties in ADL than
participants in the lowest household income quartile. For self-reported health, those who reported
good, fair, or poor health status were 4.4 (95% CI = 1.345-14.299), 16.5 (95% CI = 5.12353.252), and 59.3 (95% CI = 17.753-198.238) times more likely to have difficulties in ADL than
those with excellent health status. The number of chronic conditions also increases the likelihood
of having ADL difficulties. Having one of the following chronic conditions: hypertension,
diabetes, heart conditions, stroke, lung conditions, arthritis, and psychiatric conditions results in
increased likelihood of reporting difficulties in ADL than those who do not have those conditions
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as presented in Table 4.10. Participants with cognitive impairment were 7 (95% CI = 4.11011.933) times more likely to report ADL difficulties compared to participants with good
cognitive status. Also, depressed participants were 4.8 (95% CI = 3.455 -6.742) times more
likely to report problems than non-depressed individuals. Those who drink alcohol were 55%
(95% CI = 0.413-0.725) as likely to have difficulties in ADL than non-drinkers. Obese
participants were almost 1.9 (95% CI = 1.408-2.461) times more likely to report difficulties in
ADL than non-obese participants. Participants who never do light exercise or who exercise only
one to three time per month were 9.3 (95% CI = 5.304-16.323) and 3.3 (95% CI = 1.655 -6.427)
times more likely to develop difficulties in ADL than the participants who do light exercise
daily, while other categories of light exercise were not significant. Participants interviewed by
proxy were 10.6 (95% CI = 4.888-22.865) times more likely to report ADL difficulties compared
to participants who completed the interviews themselves.
The association between ADL at endline with gender, race, ethnicity, number of people living in
the same home with the participant, having cancer, having government health insurance, having
prescription drug coverage, smoking, and using atorvastatin were not significant. (See Table
4.10)
Table 4.10: Bivariate associations between participants’ study variables and ADL at the
endline (2008)
Predictor variable
Unadjusted OR
95% CI
p-value
Polypharmacy

3.617

2.723-4.803

< 0.0001*

Age (ref=65-74 years)

1.867

1.426-2.445

< 0.0001*

Gender (ref=male)

1.290

0.979-1.701

0.0709

Race (ref=white)
African American
Others

1.468
0.905

1.011-2.131
0.400-2.047

0.1215
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Ethnicity (ref=Hispanic)

1.088

0.658-1.800

Marital status (ref=married)
Divorced
Widowed
Never married

1.088
1.952
1.364

0.652-1.816
1.470-2.594
0.553-3.364

0.7428
< 0.0001*

Education (ref=0-6 years)
7-12 years
>13 years

0.0001*
0.503
0.333

0.302-0.838
0.195-0.571

# of people living in the home (ref=alone)
2 people
>2

0.795
1.083

0.582-1.084
0.723-1.623

Wealth (ref=lowest quartile)
Mid-low quartile
Mid-high quartile
Highest quartile

0.585
0.396
0.262

0.412-0.831
0.275-0.569
0.174-0.395

0.1485

< 0.0001*

Self-reported health (ref=excellent)
Very good
Good
Fair
Poor

2.976
0.898-9.862
4.401
1.345-14.299
16.517
5.123-53.252
59.324 17.753-198.238

< 0.0001*

Number of chronic conditions (ref=0)
1
2
3
4
5
6 -7

1.108
2.124
2.818
5.224
11.200
22.909

0.459-2.674
0.942-4.788
1.250 -6.354
2.272-12.013
4.631-27.089
7.837-66.966

Hypertension a

1.781

1.310-2.422

0.0002*

Diabetes a

2.134

1.590-2.862

<0.0001*

Heart conditions a

1.786

1.358-2.348

<0.0001*

Lung conditions a

2.215

1.536-3.193

<0.0001*

Cancer a

1.118

0.806-1.549

0.5040

<0.0001*
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Stroke a

3.343

2.354-4.748

<0.0001*

Psychiatric conditions a

3.396

2.433-4.741

<0.0001*

Arthritis a

3.266

2.265-4.711

<0.0001*

Cognitive impairment a

7.003

4.110-11.933

< 0.0001*

Depression a

4.826

3.455 -6.742

< 0.0001*

Government health insurance a

2.145

0.500-9.203

0.3045

Prescribed medication coverage a

1.118

0.444-2.813

0.8133

Smoking (ref=current)
Former
Never

1.034
1.047

0.609-1.757
0.717-1.776

Alcohol drinking (ref=no)

0.547

0.413-0.725

< 0.0001*

Obesity (ref=non-obese)

1.861

1.408-2.461

< 0.0001*

Light exercise (ref=every day)
>1 week
1 per week
1-3 per month
Never

1.059
1.617
3.261
9.305

0.614-1.828
0.922-2.837
1.655 -6.427
5.304-16.323

Using Atorvastatin a

1.202

0.836-1.728

0.3202

10.571

4.888-22.865

< 0.0001*

0.9851

< 0.0001*

Proxy interview a

* p-value < 0.05, indicates significant relationship, a= reference group is No

The 2008 cross-sectional analysis evaluated the association between ADL and the
significant variables in the bivariate analysis. Table 4.11 displays the significant variables in the
model. Polypharmacy, age, self-reported health, light exercise, arthritis, obesity, depression, and
psychiatric conditions were all significant predictors of reporting ADL difficulties at endline.
Participants with polypharmacy were 1.9 (95% CI = 1.240 3.009) times more likely to report
ADL difficulties than those without polypharmacy after controlling for other confounders. The
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adjusted OR of participants aged 75 years or older was 2.1(95% CI = 1.461-3.006) times higher
than participants aged 65-74 years. Participants reporting good, fair, or poor health status were
4.8 (95% CI = 1.002-22.647), 11.7 (95% CI = 2.477-55.392), and 28.2 (95% CI = 5.795137.210) times more likely to have ADL difficulties than participants with excellent health
status. Those who never lightly exercise were 3.6 (95% CI = 1.771-7.497) times more likely to
report ADL difficulties than those who exercise daily controlling for other confounders.
Individuals with arthritis were 2.3 (95% CI =1.322-3.851) times more likely to report ADL
difficulties after controlling for other confounders. Moreover, obese persons were 1.6 (95% CI =
1.100-2.246) times more likely to report ADL difficulties than non-obese participants. Depressed
individuals were 2.7 (95% CI = 1.711-4.203) times more likely to report ADL difficulties than
participants who were not depressed. In addition, individuals with psychiatric conditions were
1.9 (95% CI = 1.221-3.011) times more likely to experience ADL difficulties after controlling
for other confounders. The results of this analysis are presented in Tables 4.11 and 4.12. The
model had a Goodness-of-Fit Test p= 0.3367, which indicates no gross lack of fit.

Table 4.11: The predictor variables in the cross-sectional final model for ADL at endline
Variables
p-value
Polypharmacy

0.0044

Age

0.0001

Self-reported health

< 0.0001

Light exercise

0.0005

Arthritis

0.0036

Depression

< 0.0001

Obesity

0.0140

Psychiatric conditions

0.0056
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Table 4.12: The adjusted odds ratio of the predictor variables in the cross-sectional final
model for ADL at endline
Predictor variables
Adjusted OR
95% CI
Polypharmacy

1.932

1.240

3.009

Age (ref=65-74 years)

2.096

1.461

3.006

Very Good

3.926

0.900 17.126

Good

4.764

1.002 22.647

Fair

11.707

2.477 55.329

Poor

28.198

5.795 137.210

Self-reported health (ref=excellent)

Light exercise (ref= everyday)
>1 per week

1.019

0.506

2.053

1 per week

1.208

0.596

2.448

1-3 per month

2.168

0.864

5.444

Never

3.644

1.771

7.497

Arthritis

2.256

1.322

3.851

Depression

2.682

1.711

4.203

Obesity

1.572

1.100

2.246

Psychiatric conditions

1.917

1.221

3.011

Goodness-of-Fit Test p= 0.3367, N= 1502, and 43 missing observations were deleted

53

Aim 2-C) Cross-sectional study looking at the association between IADL and
polypharmacy at endline (2004)
For IADL, the bivariate analysis at baseline (2004) between IADL and study variables
without controlling for confounders resulted in the following observation: Participants with
polypharmacy did not show a significant association with IADL. Age showed a significant
association with IADL; participants aged 75 and older were 1.6 (95% CI = 1.072-2.249) times
more likely to have difficulties with IADL than participants aged 65-74 years. African
Americans were 1.5 (95% CI = 1.320-3.158) times more likely to have trouble with IADL than
white participants, while other races did not show a significant difference. Participants with 7-12
years of education were almost 35% (95% CI = 0.198-0.608) as likely to report difficulties in
IADL, and participants with 13 years or more of education were almost 19% (95% CI=0.1040.360) as likely to report difficulties in IADL than those with 6 years or less of education.
Participants living with more than two persons in the same household were 56% (95% CI =
0.359-0.861) as likely to report IADL difficulties than participants living alone. For wealth and
total household income, participants who were in the mid-low income, mid-high income, and
highest income quartiles were 50% (95% CI = 0.324-0.776), 30% (95% CI = 0.183-0.484) and
19% (95% CI = 0.109-0.338) as likely to report difficulties in IADL than participants with low
household income. In self-reported health status, those who reported fair or poor health status
were 7.1 (95% CI = 2.785-18.217) and 25.8 (95% CI = 9.624-69.207) times more likely to have
difficulties in IADL than those with excellent health status while good and very good health
status were not significant. The number of chronic conditions also increased the likelihood of
having IADL difficulties. Having one of the following chronic conditions: hypertension,
diabetes, heart conditions, lung conditions, stroke, arthritis, and psychiatric conditions would
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result in reporting difficulties in IADL more often than those who do not have those conditions
as presented in Table 4.13. Participants with cognitive impairment were 3 (95% CI =1.0828.195) times more likely to report IADL difficulties compared to participants with good
cognitive status. Also, depressed participants were 3.7 (95% CI = 2.487-5.556) times more likely
to report problems with IADL than non-depressed individuals. Former and never smokers were
57% (95% CI = 0.337-0.976) and 51% (95% CI = 0.297-0.867) as likely to report difficulties in
IADL compared to current smokers. Those who drink alcohol were 44% (95% CI = 0.301-0.635)
as likely to have difficulties in IADL than non-drinkers. Obese participants were almost 2 (95%
C I = 1.385-2.849) times more likely to report IADL difficulties than non-obese participants.
Participants who never do light exercise were 11.2 (95% CI = 3.826-32.880) times more likely to
develop difficulties in IADL than participants who do light exercise daily while other categories
in the light exercise were not significant.
The association between IADL at baseline with gender, ethnicity, marital status, having cancer,
having government health insurance, and having prescription drug coverage were not significant.
(See Table 4.13)

Table 4.13: Bivariate associations between participants’ study variables and IADL at the
baseline (2004)
Predictor variable
Unadjusted
95% CI
p-value
OR
Polypharmacy
1.284
0.904-1.824
0.1632
Age (ref=65-74 years)

1.553

1.072-2.249

0.0198*

Gender (ref=male)

0.930

0.655-1.319

0.6826

Race (ref=white)
African American
Others

1.468
0.484

1.320-3.158
0.116-2.022

0.0029*
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Ethnicity (ref=Hispanic)

1.216

0.650-2.273

Marital status (ref=married)
Divorced
Widowed/Never married

1.436
1.225

0.814-2.533
0.832-1.805

Education (ref=0-6years)
7-12 years
>13 years

0.347
0.193

0.198-0.608
0.104-0.360

0.5402
0.4341

< 0.0001*

# of people living in the home
(ref=alone)
2 people
>2

0.0307*
0.630
0.556

0.381-1.041
0.359-0.861

Wealth (ref=lowest quartile)
Mid-low quartile
Mid-high quartile
Highest quartile

0.502
0.298
0.192

0.324-0.776
0.183-0.484
0.109-0.338

Self-reported health (ref=excellent)
Very good
Good
Fair
Poor

1.430
1.771
7.123
25.808

0.528-3.872
0.671-4.674
2.785-18.217
9.624-69.207

Number of chronic conditions (ref=0)
1
2
3
4
5
6 -7

1.151
2.014
3.768
5.140
11.111
21.875

0.472-2.806
0.876-4.630
1.654 -8.588
2.124-12.441
4.021-30.703
6.175--66.966

Hypertension a

1.802

1.240-2.618

0.0020*

Diabetes a

2.138

1.442-3.169

0.0002*

Heart conditions a

2.270

1.587-3.246

<0.0001*

Lung conditions a

2.913

1.773-4.784

<0.0001*

Cancer a

1.146

0.727-1.807

0.5579

< 0.0001*

< 0.0001*

< 0.0001*
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Stroke a

3.032

1825-5.036

< 0.0001*

Psychiatric conditions a

3.067

1.947-4.767

< 0.0001*

Arthritis a

2.307

1.534-3.648

< 0.0001*

Cognitive impairment a

2.978

1.082-8.195

0.0346*

Depression a

3.717

2.487-5.556

< 0.0001*

Government health insurance a

0.581

0.240-1.405

0.2282

Prescription drug coverage
Discounts
Full price
Pay nothing
Other

0.933
0.783
0.422
1.013

0.536-1.624
0.472-1.299
0.167-1.068
0.421-2.436

Smoking (ref=current)
Former
Never

0.573
0.508

0.337-0.976
0.297-0.867

Alcohol drinking (ref=no)

0.437

0.301-0.635

< 0.0001*

Obesity a

1.987

1.385-2.849

0.0002*

1.741
2.673
1.499
11.217

0.619-4.902
0.932-7.665
0.390-5.771
3.826-32.880

1.026

0.631-1.669

Light exercise (ref=every day)
>1 week
1 per week
1-3 per month
Never

0.4174

0.0044*

< 0.0001*

Using Atorvastatin a

0.9173

* p-value < 0.05 indicates a significant relationship
The association between IADL in 2004 and the significant variables in the bivariate
analysis was then evaluated using a multivariable model. Table 4.14 displays the significant
variables in the model. Polypharmacy did not significant association after controlling for other
confounders. Self-reported health, light exercise, having heart conditions, drinking alcohol and
total household income were all significant predictors of reporting IADL difficulties at baseline.
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Participants reporting poor health status were 5.7 (95% CI = 1.440-22.552) times more likely to
have IADL difficulties than participants with excellent hath status. Those who never lightly
exercise were 5 (95% CI = 1.442-17.205) times more likely to report IADL difficulties than
those who exercise daily controlling for other confounders. Individuals with heart conditions
were 1.8 (95% CI = 1.156-2.957) times more likely to report IADL difficulties after controlling
for other confounders. For wealth and total household income, participants who were in the midlow income and highest income quartiles were 66% (95% CI = 0.438-0.989) and 36% (95% CI =
0.170-0.764) as likely to report difficulties in IADL than participants in the low household
income quartile. Results of the multivariable analysis are presented in Tables 4.14 and 4.15. The
model had a Goodness-of-Fit Test p= 0.8325, which indicates no gross lack of fit.

Table 4.14: The predictor variables in the cross-sectional final model for IADL at baseline
Variable
p-value
Polypharmacy
Self-reported health

0.5080
<0.0001

Light exercise

0.0010

Heart condition

0.0114

Psychiatric conditions 0.0629
Alcohol drinking

0.0657

Wealth

0.0342
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Table 4.15: The adjusted odds ratio of the predictor variables cross-sectional final model
for IADL at baseline
Predictor variable
Adjusted OR
95%CI
Polypharmacy

1.153

0.751

1.771

Very Good

0.991

0.279

3.525

Good

0.689

0.194

2.447

Fair

2.388

0.693

8.225

Poor

5.699

1.440

22.552

>1 per week

1.195

0.387

3.694

1 per week

1.446

0.463

4.514

1-3 per month

0.753

0.160

3.542

Never

4.982

1.442

17.205

Heart condition

1.849

1.156

2.957

Psychiatric condition

1.561

0.975

2.500

Alcohol drinking (ref=no)

0.700

0.479

1.024

Mid-low quartile

0.658

0.438

0.989

Mid-high quartile

0.551

0.300

1.013

Highest quartile

0.360

0.170

0.764

Self-reported health (ref=excellent)

Light exercise (ref= everyday)

Wealth (ref=lowest quartile)

Goodness-of-Fit Test p= 0.8325, N= 1543 and 2 missing observations were deleted
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Aim 2-D) Cross-sectional study evaluating the association between IADL and
polypharmacy at endline (2008)
The endline (2008) bivariate analysis to examine the association between IADL and
covariates yielded the following results: participants with polypharmacy were 2.6 (95% CI =
1.968-3.555) times more likely to report IADL difficulties than the group without polypharmacy.
Age significantly associated with IADL difficulty, and participants aged 75 and older were1.8
(95% CI = 1.354-2.416) times more likely to have difficulties in IADL than participants aged 6574 years. Females were 1.6 (95% CI = 1.195-2.205) times more likely to report IADL difficulties
than males. The odds of having difficulties in IADL for widowed were 2.2 compared to married
couples (95% CI = 1.604-2.965), however, divorced and never married couples did not show a
significant association. Participants with 7-12 years of education were almost 60% (95%
CI=0.349-0.692) as likely to report difficulties in IADL and participants with 13 years or more of
education were almost 33% (95% CI = 0.184-0.595) as likely to report difficulties in IADL
compared to participants with 0-6 years of education. Participants living with more than two
persons in the same household were 41% (95% CI = 0.411-0.0.886) as likely to report IADL
difficulties than participants living alone. Regarding wealth and total household income,
participants who were mid-low income, mid-high income, and highest income quartiles were
48% (95% CI = 0.327-0.692), 34% (95% CI = 0.229-0.498) and 20% (95% CI = 0.128-0.320) as
likely to report difficulties in IADL than participants with low household income. For selfreported health status, those who reported fair or poor health status were 5.6 (95% CI = 2.34613.156) and 17.5 (95% CI = 7.130-43.150) times more likely to experience difficulties in IADL
than individuals with excellent health status, while good and very good health status were not
significant. Having four or more chronic conditions increases the chances of reporting IADL
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difficulties. Having one of the following chronic conditions: hypertension, diabetes, heart
conditions, lung conditions, stroke, arthritis, and psychiatric conditions resulted in reporting
difficulties in IADL than those who do not have those conditions as presented in Table 4.16.
Participants with cognitive impairment were 10.3 (95% CI = 6.000-17.735) times more likely to
have IADL difficulties compared to participants with good cognitive status. Depressed
participants were 4.5 (95% CI = 3.184-6.437) times more likely to experience difficulty in IADL
than non-depressed individuals. Alcohol drinkers were 47% (95% CI = 0.342-0.636). as likely to
have difficulties in IADL than non-drinkers. Participants who never do light exercise or exercise
only 1-3 times per month were 9.0 (95% CI = 4.988-16.092) and 3.1 (95% CI = 1.513-6.306)
times more likely to develop difficulties in IADL than the participants who do light exercise
daily while other categories in the light exercise were not significant. Participants interviewed by
proxy were 18.4 (95% CI = 8.080-41.896) times more likely to report ADL difficulties compared
to participants who completed the interviews themselves. The association between IADL at
baseline with race, ethnicity, having cancer, having government health insurance, having
prescription drug coverage, smoking, and obesity were not significant.
Table 4.16: Bivariate associations between participants’ characteristics and IADL at the
endline (2008)
Predictor variable
Unadjusted
95% CI
p-value
OR
Polypharmacy
2.645
1.968-3.555
< 0.0001*
Age (ref=65-74 years)

1.809

1.354-2.416

< 0.0001*

Gender (ref=male)

1.623

1.195-2.205

0.0019*

Race (ref=white)
African American
Others

1.443
1.118

0.968-2.152
0.493-2.535

0.1960
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Ethnicity (ref=Hispanic)

0.865

0.485-1.545

Marital status (ref=married)
Divorced
Widowed
Never married

1.627
2.181
1.134

0.983-2.694
1.604-2.965
0.391-3.291

Education (ref=0-6years)
7-12 years
>13 years

0.603
0.331

0.349-1.041
0.184-0.595

0.6246
< 0.0001*

< 0.0001*

# of people living in the home
(ref=alone)
2 people
>2

0.0068*
0.927
0.603

Wealth (ref=lowest quartile)
Mid-low quartile
Mid-high quartile
Highest quartile

0.610-1.408
0.411-0.886
< 0.0001*

0.476
0.338
0.203

0.327-0.692
0.229-0.498
0.128-0.320

Self-reported health (ref=excellent)
Very good
Good
Fair
Poor

< 0.0001*
1.496
1.772
5.555
17.540

0.614-3.648
0.740-4.246
2.346-13.156
7.130-43.150

Number of chronic conditions (ref=0)
1
2
3
4
5
6 -7

1.328
1.848
2.049
3.644
7.000
17.231

0.559-3.158
0.816-4.187
0.898 -4.673
1.564-8.490
2.860-17.135
5.970-49.733

Hypertension a

1.483

1.076-2.044

0.0161*

Diabetes a

1.460

1.053-2.026

0.0234*

Heart conditions a

1.485

1.104-1.996

0.0089*

Lung conditions a

1.879

1.263-2.796

0.0019*

Cancer a

1.069

0.752-1.520

0.7108

< 0.0001*
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Stroke a

3.574

2.484-5.141

< 0.0001*

Psychiatric conditions a

3.851

2.726-5.440

< 0.0001*

Arthritis a

2.213

1.547-3.166

< 0.0001*

10.316

6.000-17.735

< 0.0001*

Depression a

4.527

3.184-6.437

< 0.0001*

Government health insurance a

0.778

0.262-2.308

0.6504

Prescription drug coverage a

0.929

0.345-2.497

0.8833

Smoking (ref=current)
Former
Never

0.661
0.801

0.392-1.113
0.479-1.341

Alcohol drinking (ref=no)

0.466

0.342-0.636

< 0.0001*

Obesity a

1.258

0.924-1.715

0.1453

Cognitive impairment a

0.2150

Light exercise (ref=every day)
>1 week
1 per week
1-3 per month
Never

0.884
1.395
3.089
8.959

0.493-1.587
0.765-2.544
1.513-6.306
4.988-16.092

Using Atorvastatin a

1.144

0.773-1.695

0.5012

18.398

8.080-41.896

< 0.0001*

Proxy interview a

< 0.0001*

* p-value < 0.05 indicates a significant relationship

After adding the variables in the bivariate analyses into a multivariable model to examine
their association with endline IADL, the following results were obtained: gender, age,
polypharmacy, light exercise, self-reported health status, having a psychiatric condition,
depression, and wealth were all significant predictors of reporting IADL difficulties in 2008.
Participants with polypharmacy were 1.7 (95% CI = 1.080-2.525) times more likely to report
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IADL difficulties than those without polypharmacy, after controlling for other confounders.
Participants aged 75 years and older were1.7 (95% CI = 1.044-2.673) times more likely to have
difficulties in IADL than participants aged 65-74 years, after controlling for other confounders.
Females were 1.8 (95% CI = 1.128-2.777) times more likely to develop IADL difficulties than
males, controlling for other confounders. Participants reporting poor health status were 5.4 (95%
CI = 1.595-18.041) times more likely to have IADL difficulties than participants with excellent
health status. Those who never lightly exercise were 5 (95% CI = 2.482-10.248) times more
likely to report IADL difficulties than those who exercise daily, controlling for other
confounders. Individuals with psychiatric conditions were 2.4 (95% CI = 1.407-4.015) times
more likely to report IADL difficulties after controlling for other confounders. Depressed
participants were 2.1 (95% CI = 1.268-3.534) times more likely to develop IADL difficulties
than non-depressed individuals. For wealth and total household income, participants who were
mid-high income and highest income quartiles were 50% (95% CI = 0.303-.819) and 47% (95%
CI = 0.231-0.962) as likely to report difficulties in IADL than participants in the low household
income quartile. The results of the analysis are reported in Tables 4.16 and 4.18. The Goodnessof-Fit Test had a p= 0.8568, which indicate no gross lack of fit.
Table 4.17 The predictor variables in the cross-sectional final model for IADL at endline
Variable
p-value
Polypharmacy

0.0216

Age

0.0330

Gender

0.0140

Self-reported health

0.0005

Light exercise

< 0.0001

Psychiatric conditions

0.0017

Depression

0.0049

Wealth

0.0421

64

Table 4.18 The adjusted odd ratios of the predictor variables in the cross-sectional final
model for IADL at endline
Predictor variable
Adjusted OR
95% CI
Polypharmacy

1.651

1.080

2.525

Gender (ref=male)

1.770

1.128

2.777

Age (ref=65-74 years)

1.671

1.044

2.673

Very Good

1.281

0.401

4.093

Good

1.326

0.415

4.243

Fair

2.571

0.827

7.998

Poor

5.364

1.595

18.041

>1 per week

0.749

0.380

1.475

1 per week

0.860

0.462

1.603

1-3 per month

2.165

0.892

5.254

Never

5.044

2.482

10.248

Psychiatric conditions

2.376

1.407

4.015

Depression

2.117

1.268

3.534

Mid-low quartile

0.730

0.423

1.261

Mid-high quartile

0.498

0.303

0.819

Highest quartile

0.471

0.231

0.962

Self-reported health (ref=excellent)

Light exercise (ref= everyday)

Wealth (ref=lowest quartile)

Goodness-of-Fit Test p= 0.8568, N= 1508 and 37 missing observations were deleted
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Aim 3 To assess the longitudinal relationship between polypharmacy and functional status
using a large nationally-representative dataset
Aim 3-A) To evaluate the relationship between polypharmacy status and functional status
in community-dwelling older adults after 4 years
Multiple models were developed to assess the relationship between polypharmacy status
and functional status over time (4 years). The first longitudinal model adjusted for the baseline
(2004) functional status-related variables and polypharmacy. The second model was the same
with the addition of polypharmacy status at the endline (2008). These two models were assessed
for the two outcomes, ADL and IADL. There were a total of four models (see Table 4.19).
PROC SURVEYLOGISTIC was used to run the models.
Table 4.19: Different models used to evaluate the relationship between polypharmacy
status and functional status after 4 years
Model 1
ADL at endline = Baseline functional-related variables + polypharmacy at
baseline
Model 2

ADL at endline = Baseline functional-related variables + polypharmacy at
baseline + polypharmacy at endline

Model 3

IADL at endline = Baseline functional-related variables + polypharmacy at
baseline

Model 4

IADL at endline = Baseline functional-related variables + polypharmacy at
baseline + polypharmacy at endline

All of the significant risk predictor variables examined previously in the cross-sectional
model were added to the longitudinal model, and backward elimination was performed.
Polypharmacy status was retained even if it was not significant. Table 4.19 displays the
predictors evaluated in the model between ADL (2008), the baseline polypharmacy status
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(2004), and the baseline (2004) function-related variables. Multiple interactions were added to
the model between self-reported health and polypharmacy, self-reported health and each chronic
condition, and each chronic condition and polypharmacy, but none was significant. Interactions
were checked to make sure none had a modifying role in the relationship between polypharmacy
and functional status.
In the first model, polypharmacy status at baseline was not a significant predictor of
difficulties in ADL after 4 years. Taking ≥ 5 prescribed medications at the beginning of the study
did not predict ADL difficulties at the end of the study. The important variables in the first model
to assess developing ADL difficulties in 2008 were the following baseline (2004) variables: age,
self-reported health status, arthritis, psychiatric conditions, obesity, and cognitive impairment.
Participants aged 75 years and older were 2 (95% CI = 1.348-2.987) times more likely to have
difficulties in ADL after 4 years than participants aged 65-74 years, controlling for confounders.
Participants reporting good, fair, or poor health status were 3.2 (95% CI = 1.339-7.456), 8.4
(95% CI = 3.577-19.581), and 17.5 (95% CI = 7.136-42.838) times more likely to have ADL
difficulties than participants with excellent health status. Participants with arthritis were 2.1
(95% CI = 1.381-3.306) times more likely to report ADL difficulties after 4 years than
participants without arthritis. The odds of having ADL difficulties after 4 years was 1.9 (95% CI
= 1.209-2.913) for those who have baseline psychiatric conditions, controlling for other
confounders. Obese participants at baseline were 1.7 (95% CI = 1.141-2.643) times more likely
to develop ADL difficulties after 4 years after adjusting for confounders. Participants with
cognitive impairment at baseline were 4.1(95% CI = 1.255-13.630) times more likely to develop
ADL difficulties after 4 years than participants with good cognition, after adjusting for
confounders. See Table 4.20.
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Table 4.20: Final model 1 for longitudinal analysis of ADL at endline and controlling for
baseline functional-related variables and polypharmacy at baseline
Baseline Predictor variable
Adjusted OR
95% CI
p-value
Polypharmacy 2004

1.115

0.850

1.463

0.4236

Age (ref=65-74 years)

2.007

1.348

2.987

0.0009

Self-reported health (ref=excellent)

< 0.0001

Very Good

1.609

0.733

3.534

Good

3.229

1.399

7.456

Fair

8.370

3.577 19.581

Poor

17.484

7.136 42.838

Arthritis

2.136

1.381

3.306

0.0010

Psychiatric conditions

1.876

1.209

2.913

0.0059

Obesity

1.737

1.141

2.643

0.0110

Cognitive impairment

4.135

1.255 13.630

0.0206

Goodness-of-Fit Test p= 0.2894, N= 1529 and 16 missing observations were deleted

Similar results to model 1 were obtained (Table 4.21) when adding polypharmacy status
in 2008 to form model 2. This addition resulted in a significant effect for polypharmacy status in
2008. Participants with polypharmacy in 2008 were 2.4 (95% CI = 1.666-3.570) times more
likely to report ADL difficulties than participants without polypharmacy, adjusting for all other
confounders. Polypharmacy status is important in the same year rather than 4 years earlier.
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Table 4.21: Final model 2 for longitudinal analysis of ADL at endline and controlling for
baseline functional-related variables and polypharmacy at both baseline and endline
Baseline predictor variable

Adjusted OR

95% CI

p-value

Polypharmacy 2004

1.139

0.869

1.493

0.3389

Polypharmacy 2008

2.439

1.666

3.570

< 0.0001

Age (ref=65-74 years)

1.979

1.340

2.921

0.0009

Self-reported health status (ref=excellent)

< 0.0001

Very Good

1.439

0.662

3.130

Good

2.624

1.152

5.979

Fair

6.246

2.710 14.394

Poor

12.191

4.958 29.975

Arthritis

2.085

1.347

3.228

0.0014

Psychiatric conditions

1.823

1.172

2.835

0.0087

Obesity

1.566

1.014

2.419

0.0434

Cognitive impairment

4.498

1.386 14.595

0.0133

Goodness-of-Fit Test p= 0.8730, N= 1525 and 20 missing observations were deleted

In Table 4.22, IADL in 2008 could be predicted by the following baseline variables: age,
self-reported health status, arthritis, stroke, depression, and alcohol drinking. Participants aged
75 years and older were 2.7 (95% CI = 1.870-3.914) times more likely to have difficulties in
IADL after 4 years than participants aged 65-74 years, controlling for confounders. Participants
reporting fair or poor health status were 3.1 (95% CI = 1.232-7.656) or 6.1 (95% CI = 2.46515.079) times more likely to have IADL difficulties in 2008 than participants with excellent
health status. Participants with arthritis were 1.7 (95% CI = 1.100-2.523) times more likely to
report IADL difficulties after 4 years than participants without arthritis. The odds of having
IADL difficulties after 4 years was 2.3 (95% CI = 1.393-3.905) for those who had baseline
stroke history, controlling for other confounders. Depressed participants at baseline were 1.7
(95% CI = 1049-2.760) times more likely to develop IADL difficulties after 4 years than nondepressed participants, after adjusting for confounders. Participants who drink alcohol at baseline
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were 54% (95% CI = 0.543-0.760) as likely to develop IADL difficulties after 4 years than
participants who didn’t drink, after adjusting for confounders. Polypharmacy status at baseline
was not a significant predictor for IADL difficulties. Taking ≥ 5 prescribed medications at the
beginning of the study did not predict IADL difficulties at the end of the study.
Table 4.22: Final model 3 for longitudinal analysis of IADL at endline and controlling for
baseline functional-related variables and polypharmacy at baseline
Baseline predictor variable
Adjusted OR
95% CI
p-value
Polypharmacy 2004

1.232

0.862

1.762

0.2468

Age (ref=65-74 years)

2.705

1.870

3.914

< 0.0001

Self-reported health status (ref=excellent)

< 0.0001

Very Good

1.174

0.465

2.966

Good

1.299

0.468

3.603

Fair

3.071

1.232

7.656

Poor

6.097

2.465

15.079

Arthritis

1.666

1.100

2.523

0.0170

Stroke

2.333

1.393

3.905

0.0018

Depression

1.702

1.049

2.760

0.0318

Alcohol drinking

0.543

0.387

0.760

0.0006

Goodness-of-Fit Test p= 0.6880, N= 1543 and 2 missing observations were deleted
A similar observation was seen when adding polypharmacy status in 2008 to form model
4. This addition also resulted in a significant effect for polypharmacy status in 2008. Participants
with polypharmacy in 2008 were 2.1 (95% CI = 1.460-2.872) times more likely to have IADL
difficulties than participants without polypharmacy, adjusting for all other confounders. See
Table 4.23.
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Table 4.23: Final model 4 for longitudinal analysis of IADL at endline and controlling for
baseline functional-related variables and polypharmacy at both baseline and endline
Baseline predictor variable
Adjusted OR
95% CI
p-value
Polypharmacy 2004

1.264

0.890

1.797

0.1859

Polypharmacy 2008

2.048

1.460

2.872

< 0.0001

Age (ref=65-74 years)

2.721

1.871

3.959

< 0.0001

Self-reported health (ref=excellent)

< 0.0001

Very Good

1.076

0.428

2.705

Good

1.094

0.403

2.968

Fair

2.420

0.985

5.944

Poor

4.541

1.864

11.062

Arthritis

1.601

1.045

2.452

0.0312

Stroke

2.046

1.232

3.398

0.0066

Depression

1.629

0.993

2.671

0.0532

Alcohol drinking

0.548

0.394

0.761

0.0742

Goodness-of-Fit Test p= 0.5019, N= 1539 and 6 missing observations were deleted
Aim 3-B) To assess the relationship between polypharmacy at midline and changes in
functional status after 2 years
For this specific aim, the relationship between functional status and polypharmacy was
examined after 2 years, controlling for variables in 2006. Similar models to aim 3-A have been
assessed and documented in Table 4.24. These four models were evaluated to better understand
the relationship between polypharmacy and functional decline over time.
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Table 4.24: Different models to evaluate the relationship between polypharmacy
status and functional status after 2 years
Model 5

ADL at endline = Midline functional-related variables + polypharmacy at
midline

Model 6

ADL at endline = Midline functional-related variables + polypharmacy at
midline + polypharmacy at endline

Model 7

IADL at endline = Midline functional-related variables + polypharmacy at
midline

Model 8

IADL at endline = Midline functional-related variables + polypharmacy at
midline + polypharmacy at endline

The important variables in the model 5 to predict developing ADL difficulties in 2008
were the following midline (2006) variables: polypharmacy, age, self-reported health, light
exercise, arthritis, psychiatric conditions, obesity, and cognitive impairment. Participants taking
≥ 5 prescribed medications in 2006 were 1.8 (95% CI = 1.135-2.883) times more likely to
develop ADL problems at the end of the study than participant taking < 5 prescribed
medications. Participants aged 75 years and older were 1.7 (95% CI = 1.205-2.883) times more
likely to have difficulties in ADL after 2 years than participants aged 65-74 years, controlling for
confounders. Those who never lightly exercise were 2 times more likely to report ADL problems
after 2 years than those who exercise daily controlling for other confounders. Participants
reporting good, fair, or poor health status were 3.5 (95% CI =1.277-9.783), 5.4 (95% CI = 1.69217.144) and 12.0 (95% CI = 3.837-37.349) times more likely to have ADL difficulties after 2
years than participants with excellent health status. Participants with arthritis were 2.5 (95% CI =
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1.530-4.184) times more likely to report ADL difficulties after 2 years than participants without
arthritis. The odds of having ADL difficulties after 2 years was 2.1 (95% CI = 1.177-3.870) for
those who had psychiatric conditions, controlling for other confounders. Obese participants in
2006 were 1.9 (95% CI = 1.174-2.998) times more likely to develop ADL difficulties after 2
years, after adjusting for confounders. See Table 4.25
Table 4.25: Final model 5 for longitudinal analysis of ADL at endline and controlling for
midline functional-related variables and polypharmacy at midline
Midline predictor variable
Adjusted OR
95% CI
p-value
Polypharmacy 2006

1.809

1.135

2.883

0.0138

Age (ref=65-74 years)

1.728

1.205

2.478

0.0037

Self-reported health status (ref=excellent)

< 0.0001

Very Good

1.747

0.565

5.406

Good

3.534

1.277

9.783

Fair

5.386

1.692

17.144

Poor

11.971

3.837

37.349

Light exercise (ref= everyday)

0.0633

>1 per week

0.704

0.363

1.364

1 per week

0.804

0.470

1.377

13 per month

0.972

0.455

2.077

Never

2.027

0.897

4.582

Arthritis

2.530

1.530

4.184

0.0005

Psychiatric conditions

2.134

1.177

3.870

0.0135

Obesity

1.873

1.174

2.988

0.0095

Goodness-of-Fit Test p= 0.6893, N= 1289 and 256 missing observations were deleted

In model 6, when adding polypharmacy status in 2008, the relationship between
polypharmacy status in 2006 and ADL changed from significant to non-significant (p=0.5731).
This addition also resulted in a significant effect for polypharmacy status in 2008 (p=0.0035).
Participants with polypharmacy in 2008 were 2.2 (95% CI = 1.304-3.566) times more likely to
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have ADL difficulties than participants without polypharmacy, adjusting for all other
confounders (Table 4.26).
Table 4.26: Final model 6 for longitudinal analysis of ADL at endline and controlling for
midline functional-related variables and polypharmacy at both midline and endline
Midline predictor variable
Adjusted OR
95% CI
p-value
Polypharmacy 2006

1.160 0.685 1.964

0.5731

Polypharmacy 2008

2.156 1.304 3.566

0.0035

Age (ref=65-74 years)

1.677 1.170 2.404

0.0057

Self-reported health status (ref=excellent)

< 0.0001

Very Good

1.584 0.504 4.978

Good

3.156 1.121 8.882

Fair

4.732 1.487 15.057

Poor

9.861 3.164 30.736

Light exercise (ref= everyday)

0.0405

>1 per week

0.688 0.357 1.328

1 per week

0.761 0.438 1.321

1-3 per month

0.914 0.428 1.953

Never

2.093 0.924 4.740

Arthritis

2.564 1.546 4.252

0.0005

Psychiatric conditions

2.086 1.137 3.829

0.0186

Obesity

1.837 1.145 2.947

0.0127

Goodness-of-Fit Test p= 0.4436, N= 1286 and 259 missing observations were deleted

The relationship between IADL and polypharmacy after 2 years was also examined by
similar methods used above. The important variables in model 7 to develop IADL difficulties in
2008 while controlling for the midline (2006) variables were: age, self-reported health, light
exercise, arthritis, psychiatric conditions, stroke, and wealth. Polypharmacy in this model was
not significant, however the p-value was close to significant (p=0.0636). Participants aged 75
years and older at midline were 2.3 (95% CI = 1.448-3.542) times more likely to have difficulties
in IADL after 2 years than participants aged 65-74 years, controlling for confounders.
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Participants reporting fair or poor health status were 3.4 (95% CI = 1.069-10.598) and 4.1 (95%
CI = 1.061-16.058) times more likely to have IADL difficulties after 2 years than participants
with excellent health status. Those who never lightly exercise were 3.6 (95% CI = 1.567-8.220)
times more likely to report IADL problems after 2 years than those who exercise daily,
controlling for other confounders. Participants with arthritis at midline were 1.9 (95% CI =
1.049-3.264) times more likely to report IADL difficulties after 2 years than participants without
arthritis. Participants with stroke history in 2006 were 2.1 (95% CI = 1.121-4.084) times more
likely to have IADL difficulties after 2 years, after adjusting for confounders.
The odds of having IADL difficulties after 2 years were 2.1 (95% CI = 1.230-3.471) for those
who have psychiatric conditions, controlling for other confounders. Participants who were midlow, mid-high and highest income quartiles were 50% (95% CI = 0.285-0.880), 44% (95% CI =
0.250-0.769), and 40% (95% CI = 0.174-0.914) as likely to report difficulties in IADL than
participants in the low household income quartile. (See Table 4.27)

Table 4.27: Final model 7 for longitudinal analysis of IADL at endline and controlling for
midline functional-related variables and polypharmacy at midline
Midline predictor variable
Adjusted OR
95% CI
p-value
Polypharmacy 2006

1.644 0.971

2.785

0.0636

Age (ref=65-74 years)

2.265 1.448

3.542

0.0006

Light exercise (ref= everyday)

<0.0001

>1 per week

0.687 0.377

1.252

1 per week

1.183 0.611

2.292

1-3 per month

1.180 0.427

3.263

Never

3.589 1.567

8.220

Self-reported health status (ref=excellent)

0.0045

Very Good

1.409 0.476

4.171

Good

1.191 0.383

3.703

Fair

3.365 1.069 10.598

Poor

4.129 1.061 16.058
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Midline predictor variable

Adjusted OR

95% CI

p-value

Arthritis

1.850 1.049

3.264

0.0342

Stroke

2.140 1.121

4.084

0.0220

Psychiatric conditions

2.066 1.230

3.471

0.0070

Wealth (ref=lowest quartile)

0.0160

Mid-low quartile

0.501 0.285

0.880

Mid-high quartile

0.438 0.250

0.769

Highest quartile

0.399 0.174

0.914

Goodness-of-Fit Test p= 0.8081, N= 1298 and 247 missing observations were deleted

In model 8, adding polypharmacy status in 2008 to the model for the relationship
between polypharmacy status in 2006 and IADL resulted in a significant effect for polypharmacy
status in 2008 (p = 0.0199) while polypharmacy status in 2006 remained insignificant (p =
0.6029). Participants with polypharmacy in 2008 were 1.8 (95% CI = 1.105-3.046). times more
likely to report IADL problems than participants without polypharmacy, adjusting for all other
confounders, as seen in Table 4.28

Table 4.28: Final model 8 for longitudinal analysis of IADL at endline and controlling for
midline functional-related variables and polypharmacy at both midline and endline
Midline predictor variable
Adjusted OR 95% CI
p-value
Polypharmacy 2006

1.177 0.630 2.197

0.6029

Polypharmacy 2008

1.835 1.105 3.046

0.0199

Age (ref=65-74 years)

2.212 1.420 3.446

0.0007

Self-reported health status (ref=excellent)

0.0084

Very Good

1.279 0.422 3.874

Good

1.063 0.331 3.416

Fair

2.959 0.921 9.504
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Midline predictor variable

Adjusted OR

Poor

95% CI

p-value

3.248 1.056 9.990

Light exercise (ref= everyday)

< 0.0001

> 1 per week

0.674 0.371 1.226

1 per week

1.139 0.587 2.208

1-3 per month

1.108 0.387 3.175

Never

3.715 1.614 8.549

Arthritis

1.877 1.043 3.379

0.0362

Stroke

2.091 1.114 3.924

0.0225

Psychiatric conditions

2.003 1.184 3.389

0.0106

Wealth (ref=lowest quartile)

0.0136

Mid-low quartile

0.486 0.277 0.853

Mid-high quartile

0.436 0.247 0.771

Highest quartile

0.383 0.167 0.877

Goodness-of-Fit Test p= 0.6044, N= 1295 and 250 missing observations were deleted

Sensitivity analysis (1)
In the following section, a sensitivity analysis was performed. The sensitivity analysis is
a method used to determine how different values of the exposure change the impact on the
outcome. Polypharmacy definition in this analysis was:
1) non-polypharmacy: using <5 prescribed medications
2) polypharmacy: using 5-9 prescribed medications
3) excessive polypharmacy: using 10 or more prescribed medications
At baseline, non-polypharmacy group had 986 (64.1%) participants, polypharmacy group had 470
(30.4%) participants, and excessive polypharmacy had 89 (5.5%) participants. At endline, nonpolypharmacy group had 897 (59.1%) participants, polypharmacy group had 514 (32.6%)
participants, and excessive polypharmacy had 130 (8.3%) participants. The sensitivity analysis
was done to evaluate the relationship between polypharmacy status and functional status in
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community-dwelling older adults after 4 years using different polypharmacy cut-offs. Similar
approaches to previous analyses for building different models were conducted.
Table 4.29: Different models to evaluate the relationship between polypharmacy status and
functional status after 4 years using different polypharmacy cut-offs
Model 9
ADL at endline = Baseline functional-related variables + polypharmacy and
excessive polypharmacy at baseline
Model 10

ADL at endline = Baseline functional-related variables + polypharmacy and
excessive polypharmacy at baseline + polypharmacy and excessive
polypharmacy at endline

Model 11

IADL at endline = Baseline functional-related variables + polypharmacy and
excessive polypharmacy at baseline

Model 12

IADL at endline = Baseline functional-related variables + polypharmacy and
excessive polypharmacy at baseline + polypharmacy and excessive
polypharmacy at endline

In model 9, polypharmacy at baseline was not a significant predictor of difficulties in
ADL after 4 years as seen in model 1. Taking 5-9 prescribed medications at the beginning of the
study did not predict ADL difficulties at the end of the study. Also, taking 10 or more prescribed
medications at the beginning of the study did not predict ADL difficulties at the end of the study.
The important variables in this model to assess developing ADL difficulties in 2008 were the
same as model 1 except for obesity. Refer to Table 4.30.
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Table 4.30: Final model 9 for longitudinal analysis of ADL at endline and controlling for
baseline functional-related variables and polypharmacy and excessive polypharmacy at
baseline
Baseline Predictor variable
Adjusted OR
95% CI
p-value
Polypharmacy 2004 (ref= 0-4 Rx)

0.7136

Polypharmacy (5-9 Rx)

1.133

0.838

1.534

Excessive Polypharmacy (≥10 Rx)

0.980

0.467

2.055

1.853

1.312

2.617

Age (ref=65-74 years)
Self-reported health (ref=excellent)

0.0007
< 0.0001

Very Good

1.667

0.761

3.651

Good

3.417

1.492

7.823

Fair

9.161

3.961 21.185

Poor

20.368

8.283 50.083

Arthritis

2.241

1.427

3.521

0.0007

Psychiatric conditions

1.848

1.186

2.878

0.0076

Cognitive impairment

3.788

1.183 12.127

0.0257

Goodness-of-Fit Test p= 0.5127, N= 1543 and 3 missing observations were deleted,
Rx=prescription medications
A similar observation was noted when adding polypharmacy and excessive
polypharmacy in 2008 to model 10 (Table 4.31). This addition resulted in a significant effect for
polypharmacy and excessive polypharmacy in 2008. Participants with polypharmacy in 2008
were 2.6 (95% CI = 1.663-3.909) times more likely to have ADL difficulties than participants
without polypharmacy, adjusting for all other confounders. Participants with excessive
polypharmacy at endline were 4.7 (95% CI = 2.704-8.096) times more likely to have ADL
difficulties than participants without excessive polypharmacy, adjusting for all other
confounders. Model 10 was similar to model 2.
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Table 4.31: Final model 10 for longitudinal analysis of ADL at endline and controlling for
baseline functional-related variables and polypharmacy and excessive polypharmacy at
baseline and at endline
Baseline predictor variable

Adjusted OR

95% CI

p-value

Polypharmacy 2004 (ref= 0-4 Rx)

0.7924

Polypharmacy (5-9 Rx)

1.101

0.787

1.539

Excessive Polypharmacy (≥10 Rx)

1.174

0.517

2.662

Polypharmacy 2008 (ref= 0-4 Rx)

< 0.0001

Polypharmacy (5-9 Rx)

2.550

1.663

3.909

Excessive Polypharmacy (≥10 Rx)

4.679

2.704

8.096

1.547

1.024

2.339

Age (ref=65-74 years)
Self-reported health (ref=excellent)

0.0387
< 0.0001

Very Good

1.930

0.714

5.219

Good

3.573

1.336

9.558

Fair

8.286

3.040 22.586

Poor

13.690

4.266 43.932

Arthritis

2.147

1.328

3.468

0.0024

Psychiatric conditions

2.247

1.444

3.496

0.0006

Cognitive impairment

3.452

1.174 10.146

0.0251

Goodness-of-Fit Test p= 0.7038, N= 1359 and 186 missing observations were deleted

In model 11 and 12, similar observations were also noted. Polypharmacy and excessive
polypharmacy at baseline were not significant predictors for IADL difficulties with p=0.461
(Table 4.32). While when adding them at endline, they became significant as seen in Table 4.33.
Participants with excessive polypharmacy at endline were 3.7 (95% CI = 2.401-6.608) times
more likely to have IADL difficulties than participants without excessive polypharmacy,
adjusting for all other confounders.
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Table 4.32: Final model 11 for longitudinal analysis of IADL at endline and controlling for
baseline functional-related variables and polypharmacy and excessive polypharmacy at
baseline
Baseline predictor variable
Adjusted OR
95% CI
p-value
Polypharmacy 2004 (ref= 0-4 Rx)

0.4160

Polypharmacy (5-9 Rx)

1.280

0.877

1.868

Excessive Polypharmacy(≥10 Rx)

0.945

0.430

2.077

2.710

1.871

3.926

Age (ref=65-74 years)
Self-reported health (ref=excellent)

< 0.0001
< 0.0001

Very Good

1.162

0.457

2.954

Good

1.284

0.458

3.600

Fair

3.043

1.215

7.620

Poor

6.043

2.435

14.999

Arthritis

1.667

1.099

2.527

0.0171

Stroke

2.312

1.383

3.866

0.0019

Depression

1.694

1.039

2.762

0.0351

Alcohol drinking

0.547

0.391

0.766

0.0007

Goodness-of-Fit Test p=0.6563, N= 1543 and 2 missing observations were deleted

Table 4.33: Final model 12 for longitudinal analysis of IADL at endline and controlling for
baseline functional-related variables and polypharmacy and excessive polypharmacy at
baseline and at endline
Baseline predictor variable
Adjusted OR
95% CI
p-value
Polypharmacy 2004 (ref= 0-4 Rx)

0.2021

Polypharmacy (5-9 Rx)

1.400

0.959

2.042

Excessive Polypharmacy(≥10 Rx)

1.267

0.621

2.584

Polypharmacy 2008 (ref= 0-4 Rx)

< 0.0001

Polypharmacy (5-9 Rx)

2.123

1.458

3.091

Excessive Polypharmacy(≥10 Rx)

3.673

2.041

6.608

2.448

1.679

3.570

Age (ref=65-74 years)
Self-reported health (ref=excellent)

< 0.0001
< 0.0001

Very Good

1.484

0.466

4.724

Good

1.440

0.431

4.816

Fair

3.187

1.096

9.268

Poor

6.659

2.192

20.226
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Baseline predictor variable

Adjusted OR

95% CI

p-value

Arthritis

1.606

1.037

2.489

0.0344

Stroke

1.945

1.072

3.528

0.0293

Alcohol drinking

0.534

0.357

0.799

0.0029

Goodness-of-Fit Test p= 0.5119, N= 1360 and 185 missing observations were deleted

Sensitivity Analysis (2)
In this analysis, the continuous form of ADL and IADL score were used. Also, number of
medications was used as a continuous measure. Collinearity check was done for all continuous
variables. Multiple linear regression model was used in this analysis. The first regression model
will adjust for the baseline (2004) functional-related variables and number of medications at
baseline. The second model will be the same with the addition of number of medication at the
endline (2008). Each of the two models was done to each of the continuous ADL and IADL
scores at endline.
The weighted mean for ADL at baseline was 0.186 ± 0.637, and at endline 0.294 ± 0.875.
The weighted mean for IADL at baseline was 0.129 ± 0.475, and at endline 0.249 ± 0.793.
Higher score indicates greater disabilities. The weighted mean for number of prescription
medications at baseline was 3.979 ± 3.256, and at endline 4.340 ± 3.572.
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Table 4.34: Final model 13 for linear regression model of ADL at endline and controlling
for baseline functional-related variables and number of medications at baseline
Baseline predictor variable
Estimate Standard p-value
Error
Age
65-74 years

Ref.

75+ years
Number of medications (2004)
Light exercise
Everyday

Ref.

0.2553

0.0483 <0.0001

0.0033

0.0063 0.6041
0.0023

Ref.

Ref.

> 1 per week

0.1469

0.0848 0.0831

1 per week

0.1122

0.0899 0.2118

1-3 per month

0.1221

0.1187 0.3036

Never

0.4210

0.1120 0.0002

Self-reported health
Excellent

<0.0001
Ref.

Very Good

Ref.

-0.0155

0.0729 0.8317

Good

0.0773

0.0729 0.2885

Fair

0.3362

0.0816 <0.0001

Poor

1.1755

0.1145 <0.0001

Obese

0.1390

0.0482 0.0039

Depress

0.1416

0.0678 0.0367

Arthritis

0.1300

0.0434 0.0027

Goodness-of-Fit Test p= 0.6361

Number of medications at baseline was not significant (p=0.6041) in final regression
model for ADL as an outcome (Table 4.34). Baseline characteristic: age, SRH, light exercise,
obesity, depression, and arthritis were all significant predictor for ADL difficulties at endline.
Adding the number of medications at endline resulted in significant outcomes, for each unit
increases in number of medications at endline the ADL score increases by 0.0432. (Table 4.35)
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Table 4.35: Final model 14 for linear regression model of ADL at endline and controlling
for baseline functional-related variables and number of medications at baseline and endline
Baseline predictor variable
Estimate Standard p-value
Error
Age
65-74 years

Ref.

75+ years

Ref.

0.2549

0.0475 <0.0001

Number of medications (2004)

0.0038

0.0062 0.5386

Number of medications (2008)

0.0432

0.0060 <0.0001

Light exercise
Everyday

0.0088
Ref.

Ref.

> 1 per week

0.1356

0.0834 0.1040

1 per week

0.1039

0.0884 0.2402

1-3 per month

0.0954

0.1168 0.4141

Never

0.3746

0.1104 0.0007

Self-reported health
Excellent

<0.0001
Ref.

Very Good

Ref.

-0.0451

0.0718 0.5299

Good

0.0113

0.0722 0.8755

Fair

0.2300

0.0816 0.0048

Poor

1.0320

0.1143 <0.0001

Obese

0.0926

0.0479 0.0530

Depress

0.1272

0.0667 0.0565

Arthritis

0.1030

0.0428 0.0162

Goodness-of-Fit Test p= 0.6155
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Table 4.36: Final model 15 for linear regression model of IADL at endline and controlling
for baseline functional-related variables and number of medications at baseline
Baseline predictor variable
Estimate Standard p-value
Error
Age
65-74 years

Ref.

75+ years
Number of medications (2004)
Self-reported health
Excellent

Ref.

0.3064

0.0439 <0.0001

0.0077

0.0058 0.1830
<0.0001

Ref.

Very Good

Ref.

-0.0048

0.0670 0.9426

Good

0.0126

0.0669 0.8511

Fair

0.1910

0.0741 0.0099

Poor

0.7495

0.1021 <0.0001

Arthritis

0.0967

0.0398 0.0152

Cognitive impairment

0.7074

0.1641 <0.0001

Stroke

0.3182

0.0777 <0.0001

Alcohol drinking

0.1026

0.0389 0.0083

Goodness-of-Fit Test p= 0.5465

Table 4.37: Final model 16 for linear regression model of IADL at endline and controlling
for baseline functional-related variables and number of medications at baseline and endline
Baseline predictor variable
Estimate Standard
p-value
Error
Age
65-74 years

Ref.

Ref.

0.3127

0.0435

<0.0001

Number of medications (2004)

0.0078

0.0058

0.1742

Number of medications (2008)

0.0313

0.0056

<0.0001

Ref.

Ref.

Very Good

-0.0251

0.0664

0.7058

Good

-0.0368

0.0668

0.5817

Fair

0.1119

0.0747

0.1339

Poor

0.6418

0.1030

<0.0001

Arthritis

0.0741

0.0396

0.0616

75+ years

Self-reported health
Excellent

<0.0001
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Baseline predictor variable

Estimate Standard
Error

p-value

Cognitive impairment

0.7320

0.1626

<0.0001

Stroke

0.2553

0.0778

0.0010

Alcohol drinking

0.0955

0.0385

0.0132

Goodness-of-Fit Test p= 0.5359

In the final regression model, the number of medications at baseline was not significant
(p=0.1830) for IADL as an outcome (Table 4.36). Baseline characteristic: age, SRH, arthritis,
cognitive impermanent, stroke, and alcohol drinking were all significant predictor for IADL
difficulties at endline. Adding the number of medications at endline resulted in significant
outcomes, for each unit increases in number of medications at endline the IADL score increases
by 0.0313. (Table 4.37).
The sensitivity analyses showed similar results to logistic models done in the previous
section. Polypharmacy or number of medications were important predictors in all models looking
at the relationship over time and which had polypharmacy at the endline. Categorizing the
number of medications was more clinically applicable. Also, categorizing ADL and IADL were
easier to interpret the result for clinical sittings. However, continuous measures gives more
information, and it is more sensitive to changes. It needs a smaller sample size and it give variety
of analysis options.
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Aim 4: To identify potential confounders of the relationship between polypharmacy and
functional status
Aim 4-A): To assess the role of chronic conditions in the relationship between
polypharmacy and functional status
Each of the chronic conditions and the number of chronic conditions was examined in
both cross-sectional and longitudinal models and were adjusted. The number of chronic
conditions was significant in bivariate analyses. However, it was not significant in the
multivariable models. Regarding each chronic condition, some of them, like arthritis and
psychiatric conditions, were significant in most of the multivariable models. Other chronic
conditions, like cancer, were not significant. In conclusion, some chronic conditions were
considered important confounders to the relationship between functional status and
polypharmacy.
Aim 4-B) To identify potential confounders or modifiers of the relationship between
polypharmacy and functional status
All of the previous analyses in Aims 2 and 3 were performed to identify potential
confounders and/or modifiers. Multiple interaction terms were included to identify effect
modifiers. Those interactions included interactions between: self-reported health and
polypharmacy, self-reported health and each chronic condition, and each chronic condition and
polypharmacy. However, none of the interactions were significant. All of the significant study
variables are confounders, and they change the relationship between polypharmacy and
functional status in community-dwelling older adults.
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Correlation between ADL and IADL
The Pearson Correlation Coefficients was 0.569 at baseline and 0.653 at endline. This
means there is moderate correlation between ADL and IADL and it may measure similar thing
but not exactly the same. It is known that ADL focus more on the physical activities of daily
living and IADL focus in more complex aspects of instrumental activities of daily living. This
explains the moderate correlation we see between ADL and IADL. We need both to get a better
understanding of functional decline.
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Chapter 5 Discussion

5.1 Descriptive data discussion
This study showed that polypharmacy was significantly associated with functional
decline in cross-sectional and longitudinal analyses. A stronger association was found at the end
of the study. Our results are similar to others studies that examined the association between
functional status and polypharmacy (Jay Magaziner et al. 1989; Jyrkkä et al. 2011b; Lau et al.
2011). Other confounders were also important such as self-related health, age, and arthritis in the
longitudinal analyses. In all cross-sectional analyses self-reported health and light exercise were
also associated with functional status. The baseline demographics reported in this study are
similar to those reported in other studies using the same HRS and PDS files (Zivin et al. 2009;
An and Lu 2015). In Table 4.1, we can recognize that 16.2% of participants reported ADL
difficulties and 13.8% of participants reported IADL difficulties in 2008. Both percentages
increased 4.7% from 2004 to 2008. ADL difficulties were slightly more common than IADL
difficulties. A similar trend was observed in a study using the same HRS dataset waves, and
showed that ADL difficulties were reported slightly higher than IADL difficulties (An & Lu
2015). Overall, the proportion of the population reporting functional limitations was low in our
study population compared to other studies like the National Health and Aging Trends Study
which reported that 48.3% of participants experienced difficulty and received help from another
person with ADL (Freedman & Spillman 2014). Under-reporting of functional limitations is
common in community-dwelling older adults until it is no longer tolerable, , and it may be
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attributable to the threat of loss of independence (Guccione et al. 1994; Fried and Guralnik
1997). Other explanations for under-reporting are participants may limit the frequency of doing a
duty to the minimum essential effort, or sometimes increase the frequency of a task but do less
work at any one time. Also, they could change the way they do the task to minimize the effort,
for example, lean on the shopping cart and report no difficulties (Fried and Guralnik 1997; Saliba
et al. 2000). Our study population was also relatively healthy, as most of them reported very
good to good health status. It is interesting to mention that older adults often interpret selfreported health (SRH) in general as their health compared to other people of similar age, which
means that they might have some health issues but considering their age they think they are
healthy (Chen et al. 2016). Also, a non-polypharmacy group is three times more likely to report
good SRH than a polypharmacy group (Agbor et al. 2013). In our study, we have more nonpolypharmacy than polypharmacy participants compared to this study.
The prevalence of polypharmacy was similar to what was reported in the literature. It was
reported in previous studies that the prevalence of older adults taking more than five medications
is 36% to 39% (Charlesworth et al. 2015; Levy 2017). In our study, 35.9% reported
polypharmacy status, and it increased to 40.7%. One potential reason for this increase in our
study population was that Medicare Part D for prescription drug coverage had been
implemented. Atorvastatin was the most common medication used in the study. It is also the
most commonly used statin worldwide (Patel et al. 2013). Statins are prescribed to prevent
cardiovascular diseases and lowering cholesterol levels. Statins side effects can include muscle
weakness and fatigue. A randomized control study showed a relation between statin usage and
fatigue which could lead to functional decline (Golomb et al. 2012). In our study, we only tested
one medication from the statins class, which was Atorvastatin, as a confounder, but the results
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were not significant. One study in Australia reported a low statin–drug interactions and that
statins do not interact with many other medications which could explain the non-significant
results we had in our results (Thai et al. 2015). However, we cannot rule out that there is no
association between all statins as a class of drug and functional decline and further studies to
look at the relation between statins and functional status is recomended. The HRS does not have
enough information about drug classes and each participant was asked to write a list of all the
medications prescribed, including those taken occasionally. And if they were more than ten
medications, then participants choose what he/she consider the most important. So, we cannot
tell if the participants were taking statins or not. Another explanation might be that the
relationship between polypharmacy and functional status is not simply due to the use of drugs
like statins whose side effects (muscle weakness, fatigue) in older adults but due to using a large
number of medications together.
About 70% of participants used drug chain stores, mail orders pharmacies, and
independent pharmacies as the source of getting their prescribed medications. One study reported
that drug chains and independent pharmacies accounted for 40% and 35% of all pharmacies in
the US (75% in total), which is consistent with the most common source identified in this study.
Different types of insurances were also used, and 55% of participants paid some of the costs of
their prescribed medications and the insurance paid the rest. Having governmental insurance or
prescription drug coverage were not significant as variables affecting the relationship between
polypharmacy and functional outcomes in all the bivariate analysis and longitudinal models.
Our study showed we had 13 non-responses in the endline, which were deleted from the
study. All the non-responses were code 4, meaning that the participants were alive as far as we
know but did not respond. It is important to look at non-responders, especially if they were
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deceased because the results might then be attenuated. Since our non-responders were alive and
their sample size is very low, then deleting them should not affect our results significantly.

5.2 Functional status and polypharmacy in cross-sectional analyses
Looking at the cross-sectional models, we can conclude that polypharmacy was an
important predictor for ADL in both bivariate and multivariable analyses. After controlling for
confounders, the odd ratio between polypharmacy and ADL increased from 2004 to 2008,
OR2004 = 1.4 (p = 0.0256) and OR2008 = 1.9 (p = 0.0044). After 4 years, participants with
polypharmacy were almost 90% more likely to report ADL difficulties than non-polypharmacy
participants, compared to the beginning of the study where the participants with polypharmacy
were 40% more likely to report ADL difficulties than non-polypharmacy participants. For IADL,
both the adjusted and unadjusted analyses at the baseline did not show an association between
IADL and polypharmacy status (adjusted OR2004 = 1.2; p = 0.5080). However, in 2008 the
association became significant (p = 0.0216), and the OR increased to OR2008 = 1.7. Similar
results for IADL decline after 3 years were also described in Jyrkka et al (Jyrkkä et al. 2011b).
The change in the association from not significant to significant and the rise in the OR might be
due to Medicare Part D implementation and the availability of prescription drug coverage. In
2006, Medicare Part D was implemented and provided prescription drug coverage for older
adults through private health plans. This coverage could lead to increased polypharmacy status
leading to a decline in IADL. One study reported similar results demonstrating a stronger
association between ADL decline and polypharmacy and significant but a weaker association
between IADL and polypharmacy (Jay Magaziner et al. 1989). Marital status could be another
explanation, as we noticed 7.6% of married people in 2004 became widowed by 2008. IADL
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include food preparation, shopping, medication administration, using the telephone, and
managing money. Those listed items in IADL could be performed with the help of a caregiver.
However, the number of people living in the same house, and marital status were not a
significant predictor for functional decline in the adjusted analyses. Our results are similar to the
cross-sectional study discussed in the literature review chapter. Connolly et al. reported a
stronger relationship between ADL and polypharmacy than IADL and polypharmacy (Connolly
et al. 2017).
5.3 Confounders in cross-sectional analyses
The confounder is a variable that influences both the outcome (functional status) and the
exposure (polypharmacy) causing a false association. In order to be a confounder, it needs to be a
risk factor for both exposure and outcome and not to be in the causal pathway. We can identify
potential confounders from previous knowledge, common sense, or meeting the three criteria
listed above.
In the adjusted cross-sectional analyses, self-reported health (SRH) and light exercise
were the two variables that were present in all cross-sectional models for both outcomes ADL
and IADL. Self-reported health was also recognized in the literature to be a significant predictor
of negative outcomes including functional decline and mortality (Fonta et al. 2017; Cesari et al.
2008). The poorer the SRH, the more medications are prescribed. Therefore, it influences both
number of medications and functional decline. Regular exercise, ranging from light to vigorous,
has been shown to decrease the risk of mortality and negative health outcomes including
disability (Fonta et al. 2017). Interaction terms between SRH and polypharmacy and other
chronic conditions were conducted, and none were significant. For exercise, it is well established
that a sedentary lifestyle can increase the risk of heart disease, stroke, and functional limitations.
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Increasing the number of comorbid conditions will also increase the number of prescribed
medications and thus polypharmacy status. It is important to mention that exercise can reverse
some of the health consequences when individuals start to exercise regularly (Rosenkranz et al.
2013).
Also, in the ADL and IADL cross-sectional analyses we can realize that psychiatric
conditions were included in the final model in 2004; however, the p-value was < 0.10 and higher
than our significance level of 0.05. The psychiatric conditions in 2004 for ADL and IADL had a
p = 0.0891 and p = 0.0629 respectively. While in 2008, the psychiatric disorders for ADL and
IADL had a p = 0.0056 and p = 0.0017 respectively. The psychiatric condition is a mental illness
diagnosed by a mental health professional, and it affects mood, behavior, and thinking abilities.
It can cause great harm to the person's life leading to disability and death. Since functional status
needs both physical and mental ability, the presence of psychiatric problems could disturb a
person's ADL and IADL. It has been shown that there is a relationship between psychiatric
disorders and decline in both ADL and IADL (Kivelá & Pahkala, 2001; Mograbi et al. 2017).
Likewise, persons with psychiatric conditions tend to have more prescribed medications than
those who have not been diagnosed with a psychiatric condition (Lau et al. 2011). Since
depression is often a part of psychiatric disorder, an interaction term between psychiatric
conditions and depression was evaluated, and it was not significant.
We observed that the final models for ADL in 2004 and 2008 were similar and had
similar predictors. In addition to polypharmacy, SRH, and light exercise (and psychiatric
conditions in 2008), we noticed that obesity and depression were present in all cross-sectional
analyses with ADL difficulties as an outcome. There are many longitudinal and cross-sectional
studies that reported the association between ADL disabilities and obesity, and a limited number
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of studies reported the association between IADL disabilities and obesity (Okamoto et al. 2018;
Cesari et al. 2008; Himes 2000). A study that used HRS as the data source also showed that
obesity, defined as BMI ≥ 30 kg/m2, was associated with ADL decline (Sturm et al. 2004).
Obesity prevalence in older adults is increasing, and is linked to many factors including
sedentary lifestyle, change in metabolic rate, and change in diet (Arteburn 2004). Obesity is
linked to many comorbid conditions including heart disease and cancers. It has been
hypothesized that obesity and big body size could be linked to a decline in functional status by
limiting mobility. The excess weight can also affect joint flexibility, decrease muscle strength,
and reduce the capacity to exercise. Another study hypothesized that obesity would increase the
risk of chronic conditions and thus it will increase both the number of prescribed medications
and functional decline (Gibbs et al 2005). For depression, it has been reported that there is an
association between depression and functional decline, but it is not clear whether the depression
leads to functional decline, or if the functional decline leads to depression (Zivin et al. 2009;
Mograbi et al. 2017; Kivelá and Pahkala 2001). Depression also increases the number of
prescribed medications. The long term use of antidepressant medications is also associated with
functional decline (An & Lu 2016).
In the final model for IADL at 2004 and 2008, wealth was an important confounder. It is
well documented that low socioeconomic status is associated with poor health, disability, and
premature mortality (Torres et al. 2016). Higher economic status allows individuals to have
better access to healthcare facilities and medications. Moreover, individuals with a higher
economic status are more likely to have good social support, spouses, and more friends. Torres et
al. showed a negative relationship between wealth and difficulties in ADL and IADL.
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Some additional confounders were found in the IADL or ADL final model. Arthritis was
an important risk factor in the final model of ADL difficulties in 2008. Arthritis was also in the
final model of ADL difficulties in 2004; however, it was not significant (p = 0.0598). Patients
with arthritis are more likely to have functional disabilities (Marques et al. 2016). Arthritis is
also associated with polypharmacy in long-term care facilities (Jokanovic et al. 2015). Gender
was also included in our final model for IADL in 2008. Many studies have identified that
females are more likely to have polypharmacy and are at higher risk of polypharmacy
consequences since body fat increases as a part of aging in females to a greater extent than males
(Jay Magaziner et al. 1989). Also, females are more likely to take prescribed medications. They
are also more likely to report poor SRH and disability (Fonta et al. 2017).
Alcohol drinking also appeared in the final cross-sectional model for IADL in 2004.
Those who drink alcohol were 70 % as likely to report IADL difficulties than nondrinkers.
Similar results were also found in a systematic review. Many studies in the review found that
nondrinkers are at higher risk for functional difficulties compared to moderate drinkers (Stuck et
al. 1999). In addition, individuals with poor health might stop drinking, and that might explain
these results. Heavy drinkers, on the other hand, are at greater risk of functional decline and
drinking increases the risk of drug interactions. Alcohol concentration is higher in older adults
for the same amount consumed in younger adults because of the change of body composition
with more body fat and less body water (Delafuente 2008). Additionally, heart conditions
appeared in the final cross-sectional model for IADL in 2004, and they are a well-known risk
factor for polypharmacy. Patients with angina and myocardial infarction will be automatically on
at least 5 prescribed medications according to practice guidelines (Schwinger 2018; Jokanovic et
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al. 2015). Heart conditions are also a risk factor for functional decline as reported in Stuck et al.
1999.
5.4 Functional status and polypharmacy in longitudinal analyses
In the adjusted models looking at the four-years (2004-2008) relationship between
polypharmacy and our main outcomes ADL and IADL, we noted that polypharmacy status at
baseline (2004) was not an important predictor for functional decline (model 1 and 3); however,
adding polypharmacy status for the endline (2008) was an important predictor (model 2 and 4).
The odds for reporting ADL and IADL decline in 2008 were 2.4 (95% CI = 1.666-3.570) and 2.1
(95% CI = 1.460-2.872) times more likely in participants with a 2008 polypharmacy status.
Looking at the two-year (2006-2008) relationship between polypharmacy and functional
status, we recognized that polypharmacy status before 2 years was important (ADL p = 0.0138,
IADL p = 0.0636 [borderline significance]) (model 5 and 7). When adding polypharmacy status
for the endline (2008) to model 6 and 8, polypharmacy status at 2006 was no longer significant
(ADL p = 0.5731, IADL p = 0.6029). This means that polypharmacy status of the same period
was more important than two years prior. This result is similar to that observed in another study
that concluded that polypharmacy cannot predict functionality over a three-years period (Jyrkkä
et al. 2011b). Polypharmacy of the same year was significant in almost all cross-sectional models
with one exception (discussed above), and in all longitudinal models which had polypharmacy at
the endline as a predictor. As a result, we can conclude that polypharmacy is an important
predictor of functional decline and it might not have the long-term relationship (4 years) but
rather two years or less. It interrupts participant’s functional status around the same period rather
than contributing to future decline. This might be due to the acute effects of drug-drug
interactions, or PIMs. Patient could have been in poor health or experienced a health event that
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led to an increase in prescribed medications and eventually functional decline. Also, the low
number of prescribed medications used by most participants in HRS (participants with
polypharmacy were fewer than participants with no polypharmacy) could contribute to the lack
observation of a long-term relationship. We also had a low percentage of participants who
reported functional decline and our population were mostly healthy, which could also contribute
to not seeing a long-term relationship. Previous studies that showed long-term relationships had
more participants with polypharmacy than in our study and they included OTC medications to
determine polypharmacy status. Our study did not include OTC medications, which is an
important factor for the number of medications, especially if they are being taken regularly. Not
including OTCs is one of our study limitations. Also, the populations of previous studies had
more health conditions with more participants reporting poor SRH. In addition, we did not
exclude participants with functional decline at the baseline, this gave us different starting points
for our participants and might influence the results.
In the observed association between polypharmacy and functional decline after 2 and 4
years the number of medication itself may not be the cause, but rather it is a contributing cause
where the benefits may outweigh the risks for some patients and vice versa. Functional decline
also occurs in the absence of polypharmacy. This suggests that polypharmacy may be a good
predictor or indicator for early detection of functional decline.
5.5 Confounders in longitudinal analyses
Age, SRH, and arthritis were confounders in all the adjusted longitudinal analyses for
both outcomes ADL and IADL. Age is a well-known risk factor for both functional decline and
polypharmacy. 19.4% of our participants had a shift in age categories from 65-74 years to 75+
years during the 4 years (Table 4.1). Aging is associated with physiological changes that include
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decreased hepatic and renal function, changes in body composition, decline in baseline
performance and decreased homeostatic reserve. These physiological changes can cause changes
in drug pharmacokinetics (absorption, distribution, metabolism, and elimination), or
pharmacodynamics (receptor and drug action on the body) often resulting in increased drug
exposure and exaggerated drug (Bushardt et al. 2008; Jokanovic et al. 2015). SRH is the only
confounder that was present in all models (cross-sectional and longitudinal). This supports the
idea that functional status reflects the health status and independency of people. SRH seems to be
a very important predictor, and this means that we should pay attention to participants reporting
fair or poor health and having polypharmacy because they are at higher risk of reporting
functional decline. In this case, we can see polypharmacy as a risk factor, and managing
prescribed medications for patients who report fair to poor health as mandatory. On the other
hand, for patients reporting excellent and good health status, polypharmacy might be appropriate
with no need for modification. Multiple medications do not always have to be problematic (
Levy 2017). Some older adults are on multiple medications, and they are healthy, while others
would be in better health if their medications were fewer. Regardless, it is important to ensure
that for all medications the benefits outweigh the risks for the individual patient.
Regarding the longitudinal models with ADL as the main outcome, obesity and
psychiatric conditions were the additional confounders that presented in all longitudinal models,
whereas the IADL model had stroke as a confounder. Stroke affects the neuromuscular system
and could affect the functional status depending on the prognosis and severity. Stroke was found
in the Framingham study to be the most strongly associated with grocery shopping dependence
(Guccione et al. 1994). Shopping is one of the items in IADL, and so this could be the
explanation of the IADL decline associated with stroke observed in our study. Lastly, cognitive
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impairment was a confounder for the association between ADL and polypharmacy in Models 1
and 2 (4 years association). In our study, cognitive impairment was associated with ADL decline.
Cognitive impairment has been shown to be related to polypharmacy (Silay et al. 2017). Also,
functional decline is associated with cognitive impairment (Ho et al. 2018).
Since functional decline is reversible in some cases and polypharmacy could be adjusted
and monitored to give better outcomes, then we should pay attention to the modifiable risk
factors we found in our study (alcohol use, exercise, BMI) along with a prescribed medication
checkup. Monitoring risks factors for functional decline could change patient status from
dependent to independent or at least slow the progression of functional decline.

5.6 Strength and limitation
Using a nationally representative dataset not previously evaluated was a strength to our
study. Another strength was controlling for some chronic conditions and the number of chronic
conditions. Both cross-sectional and longitudinal analyses were conducted in our study to better
understand the relationship. Looking at multiple time points and providing a sensitivity analysis
which looked at excessive polypharmacy strengthened our study.
One major limitation of this study is the use of self-reported data. The accuracy of selfreported information is dependent on a variety of factors including participants’ understanding of
the questions, willingness to be honest with the interviewer about potentially embarrassing topics,
bias towards providing socially-desirable responses, and mood and mental status at the time of
interview. Despite controlling for many confounders in our observational study, we cannot
eliminate the confounding bias due to non-randomized design of our observational study, and thus
our result is association rather than causation.
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Another limitation is the inclusion of only those participants with complete functional and
medication data at both baseline and endline, which limited our study population. Other limitations
of this study include a lack of data on health conditions other than the eight chronic diseases
included in the HRS, the severity of the chronic conditions mentioned in the "Measures" section
and a lack of information about over-the-counter medication use. It is also not possible to examine
the use of potentially inappropriate medication because this would require an individual
assessment of each participant's prescription list and health history. The generalizability of this
study is limited to community-dwelling adults in the United States, and findings may not apply to
institutionalized adults or adults in other countries.
Finally, an important limitation is the time when the data was collected, more than 10 years
ago. Prevalence of polypharmacy, access to healthcare and other factors may have changed during
the past ten years. This dataset remains a valuable resource to assess the relationships between
polypharmacy and functional status however.
5.7 Conclusion
Polypharmacy is a good predictor or indicator for early detection of functional decline.
Polypharmacy status of the same year showed a significant association with functional decline in
cross-sectional, and in all longitudinal models which had polypharmacy at the endline as a
predictor. Many confounders were found to be significant. SRH and light exercise were
associated with functional decline in all cross-sectional analyses. SRH, age and arthritis were
important confounders for the longitudinal analyses.
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5.8 Future directions
Since both polypharmacy and functional decline are modifiable and preventable, then it
would appropriate to conduct additional observational studies (prospective cohort) and look for
possible reasons behind the observed association, confirm the observed association, and try to
overcome the limitations in the studies to date. Future studies should enroll participants with no
functional decline at the beginning of the study, follow them over time, gather information
regarding prescribed and OTC medications taken regularly, and record detailed information
regarding dosage, frequency, indication of prescriptions, side effects, and any special instruction.
The medications should be checked by pharmacists for PIM including medications on the Beer’s
list, drug-drug interactions, drug-disease interactions, duplications, inappropriate dosing, and
unnecessary medication (no indication for usage). Also, access to participants’ medical records
to check for an appropriate indication of the medications would be valuable. The severity of
participants’ chronic illness should be accounted for as well.
Our study would help health care providers and policy makers target at risk populations
for interventions and help older adults maintain independence. Future studies examining specific
medication classes and their relationship to functional decline could help in designing
interventions. Also, implementing an intervention study for de-prescribing, or intensive
medication review to evaluate functional status as an outcome would help to better understand
this relationship.
Our study may also have implications for the annual Medicare Wellness Visit that is part
of Medicare Part B. During the first Medicare Annual Wellness Visit (AWV)
(medicareinteractive.org), the following should be assessed:
1) Height, weight, blood pressure, and other routine measures.
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2) Health risk assessments about health status, injury risks, behavioral risks, and urgent
health needs.
3) Functional ability of ADL and level of safety (includes risk of falling, and level of
safety)
4) Medical and family history
5) Current prescription medications, as well as vitamins and supplements, and durable
medical equipment (DME) suppliers.
6) Cognitive impairment, including diseases such as Alzheimer’s and other forms of
dementia
7) Depression

Based on this assessment, the provider should create a written 5-10 year screening schedule
or check-list as well as provide appropriate health advice and referrals to health education
and/or preventive counseling services aimed at reducing identified risk factors and promoting
wellness which includes: weight loss, physical activity, smoking cessation, fall prevention,
nutrition, and more.
The following visit will be conducted according to patients’ needs and written plan. The
annual visit is very good opportunity to address issues around polypharmacy and functional
status in older adults. Based on our study, considering polypharmacy, functional status, and other
confounders I propose the following approach to incorporate our findings into patient care
(Figure 5.1):
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1) If the patient is between 65 and 74 years of age, has no difficulty in both ADL and IADL,
no polypharmacy, or SRH is excellent-good, then there is no need for intervention, and
follow up can occur after one year.
2) If the patient is 75 years or older, has difficulty in ADL, has difficulty in IADL, has
polypharmacy, or SRH is fair-poor, then full medication review is recommended, along
with assessing for modifiable risk factors and controlling chronic conditions, and
individualize an appropriate intervention to reduce risk.
This could be incorporated into the annual visit by identifying participants who need
immediate attention, and others who can be seen in the following year. Also, once identifying the
risk group, a full medication review is recommended to identify PIMs, medications to avoid in
Beer’s list and drug-interactions. Moreover, a full medical history and lab work for chronic
conditions should be performed to guide better management of chronic disease.
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Figure 5.1 Guidelines for standard care in community-dwelling older adults
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Appendix

Table A: Medications drug survey data variables (2005 and 2007 PDS, and 2009 HWB) and
SAS code
Variable/ Name
before merge
Merge variables

Name after merge

Notes

Number of
medications

Pds05_medsintable

Number scripts in
table provided in the
questionnaire

Name of medications

Pds05_P1DRUGNAME1

Drug name from 1 to
10

Medication brand
name

Pds05_1BRANDNAME

Brand name from1-10

Medication: How long
taking /P1E2
# Prescribed
medications in last
month/P1A3
# Prescribed
medications regularly
/P1A4

Ppds05_duration

Duration of use for
each drug from 1to 10

What type of
pharmacy
Prescription drug
coverage P1B1

Pds05_P1A7A

HHID, PN, POSITION

Pds05_P1A3

Dataset PDS05
HHID and PN all
sections, position
section E
Not in data, built
during merge from
section E.
MAX(position)
Not in data, built
during merge from
section E
Not in data, built
during merge from
section E
Section E
Section A

Pd05_P1A4/ Polybase

Pds05_P1B1
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Categorized into
Polypharmacy
baseline <5 prescribed
medications, ≥5
prescribed medications
From A-J

Section A

1.I pay some of the
price and insurance
2. I get a small
discount
3. I pay full price for
all medications
4. I don't pay
anything.
5. Other

Section A

Section A

Source of prescription
insurance (yes/no by
category)/P1b8a-g
Any side effects
Action in response to
side effects (yes/no by
category)
Questionnaire by
proxy/P1H1
Sample weights and
completion status
Merge variables for
PDS07

Pds05_p1b8

Pds05_p1b8a -g

Section A

Pds05_P1C2
Pds05_P1C3A-F

SKIP=0

Section A
Section A

# Prescribed
medications regularly/
P2A4

Pds07_P2A4/polymed

Prescription drug
coverage /P2B1

Pds07_ P2B1

Merge variables

HHID, PN

# Prescribed
medications regularly
/P3A4

Hwb09_P3A4/polyend

Prescription Drug
coverage/P3A1B

hwb09_P3A1B

* PDS07 dataset

** HWB09 dataset

Pds05_P1H1

Section A

P1QX, P1MED, P1QXWT,
P1QXMED
HHID, PN, POSITION,
POSITION_F

Section S

Categorized into
Polypharmacy middle
<5 prescribed
medications, ≥5
prescribed medications
1.I pay some of the
price and insurance
2. I get a small
discount
3. I pay full price for
all medications
4. I don't pay
anything.
5. Other

Categorized into
Polypharmacy end line
<5 prescribed
medications, ≥5
prescribed medications
Yes, no
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All sections (position
only in section E and
F) *
Section A*

Section A*

All sections (A and S)
**
Section A**

Section A**

Table B: Functional status variables and SAS codes
Variable
ADL
Summary
score
Bathing
Dressing
Eating
Getting in
or out of
bed

Name

Name after merge and coding

RwADLA

R7ADLA/R8ADLA/R9ADLA

RwBATHA
RwDRESSA
RwEATA
RwBEDA

R7BATHA/R8BATHA/R9BATHA
R7DRESSA/R8DRESSA/R9DRESSA
R7ETA/R78EATA/R9EATA
R7BEDA/R8BEDA/R9BEDA

Walking

RwWALKRA

R7WALKRA/R8WALKRA/R9WALK
RA

IADL
Summary
score
Phone

RwIADLA

R7IADLA/R8IADLA/R9IADLA

RwPHONEA

Notes
Summary score
were recoded into
(yes, no) for having
functional
limitations and
adlbase/adlmed/
adlend

Dataset

RAND
RAND
RAND
RAND

RAND
Summary score
were recoded into
(yes, no) for having
functional
limitations and
Iadlbase/
Iadlmed/
Iadlend

RAND

Money

RwMONEYA

Medication
Administra
tion
Shopping

RwMEDSA

R7PHONEA/R8PHONEA/R9PHONE
A
R7MONEYA/R8MONEYA/R9MONE
YA
R7MEDSA/R8MEDSA/R9MEDSA

RwSHOPA

R7SHOPA/R8SHOPA/R9SHOPA

RAND

Meals

RwMEAL

R7MEAL/R8MEAL/R9MEAL

RAND
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RAND
RAND
RAND

Table C: HRS study variables and SAS code
Variable
Age

Name
RwAGEY_B

2004/2006/2008
Age /age2_/age3_

Sex (male,
female)
Race (white,
black, other)
Hispanic (yes, no)

RAGENDER

RAGENDER

RARACEM

Race

RAHISPAN

Race

Education (years)
Household income

RAEDYRS
HwITOT

Edu
Wealth/wealth2_/wealth3_

Number of people
in house including
respondent and
spouse
Self -reported
Health status
(poor, good,
excellent)
Marital status
(Married,
divorced,
widowed, never)

HwHHRES

People/people2_/people3_

RwSHLT

R7SHLT/R8SHLT/R9SHLT

RwMSTAT

Mstat/mstat2_/mstat3_

# household
residents,
including
respondent and
spouse
Insurance status
Government
Employer
Spouse’s
employer
Other
# Health ins plans

HwHHRES

Converted
into
categorical
(65-74Y,
75+Y)

Dataset
RAND

RAND
Non-Hispanic
white
Non-Hispanic
black
Others
Hispanics

RAND
RAND

RAND
Converted
RAND
into
categorical by
quartiles
Converted
RAND
into (alone, 2
persons, more
than 2)
RAND

I had to make RAND
a new
recategorize
for mstat4_
because never
had 0
participants
RAND

RwHIGOV
RwCOVR
RwCOVS

R7HIGOV/R8HIGOV/R9HIGOV
R7COVR/R7COVR/R8COVR
R7COVS/R8COVS/R9COVS

RAND
RAND
RAND

RwHIOTHP
RwHENUM

R7HIOTHP/R8HIOTHP/R9HIOTHP
R7HENUM/R8HENUM/R9HENUM

RAND
RAND
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Depression (yes,
no)

RwCESD

Depress/depress2_/depress3_

Cognitive
impairment (yes,
no)

RwCOGTOT

Cog/cog2_/cog3_

Obesity (yes.no)

RwBMI

Obese/obese2_/obese3_

RwVGACTX

R7VGACTX/R8VGACTX/R9VGACTX

Exercise
Frequency
vigorous
1.Every day
2.>1 per week
3.1 per week
4.-3 per month
5.Never
Frequency light
1.Every day
2.>1 per week
3.1 per week
4.-3 per month
Smoking
Ever
Current

Alcohol (Yes, no)
Chronic diseases
Total number
Hypertension
Diabetes
Cancer
Lung disease
Heart disease
Stroke
Psychiatric
Arthritis
Proxy interview
Institutionalization
status (living in
nursing home or

Recoded to
no if score ≤3
or yes if >4
Recoded to
no if score
>10 or yes if
≤10
Recoded to
no if score
<30 and yes
if score≥30

RAND

RAND

RAND

RwLTACTX

RAND

SOMKER/SOKER2_/SMOKER3_
RwSMOKEV
RwSMOKEN

It was
recategorized
into 1-current
smoker
2-former
smoker
3-never
smoker

RAND
RAND

RwDRINK

R7DRINK/R8DRINK/R9DRINK

RAND

RwCONDE
RwHIBPE
RwDIABE
RwCANCRE
RwLUNGE
RwHEARTE
RwSTROKE
RwPSYCHE
RwARTHRE
RwPROXY
RwNHMLIV

R7CONDE/R8CONDE/R9CONDE
R7HIBPE/R8HIBPE/R9HIBPE
R7DIABE/R8DIABE/R9DIABE
R7CANCRE/R8CANCRE/R9CANCRE
R7LUNGE/R8LUNGE/R9LUNGE
R7HEARTE/R8HEARTE/R9HEARTE
R7STROKE/R8STROKE/R9STROKE
R7PSYCHE/R8PSYCHE/R9PSYCHE
R7ARTHRE/R8ARTHRE/R9ARTHRE
R7ROXY/R8PROXY/R9PROXY
R7NHMLIV/R8NHMLIV/R9NHMLIV

RAND
RAND
RAND
RAND
RAND
RAND
RAND
RAND
RAND
RAND
RAND
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health care
facility)

122

VITA

DUAA MOHAMED BAKHSHWIN
bakhshwindm@vcu.edu

Education:
PhD candidate

Virginia Commonwealth University (VCU) School of pharmacy Richmond, VA, USA

May 2018

Master of Science in pharmacology
May 2014
Virginia Commonwealth University (VCU) School of medicine Richmond, VA, USA
• Thesis: autophagy inhibition by Chloroquine in HN30 head and nick cancer cell is the cause
of radio sensitization, advisor: Dr. David Gewirtz, Professor of Pharmacology up to date
GPA 4.0.
Bachelor degree of Medicine & surgery

King Abdul Aziz University, Jeddah, Saudi Arabia
• with 2nd honor degree 83.2% (B+) GPA 4.16 out of 5.0.

June 2009

High school Diploma
June 2003
Altheker High school, Jeddah ,Saudi Arabia.
• with an excellent score, 99.89..% ( A+ ) , gained the 5th highest score upon Saudi
Arabia students & the 2nd highest score upon Jeddah students.

________________________________________________
Current Position:

PhD student at pharmacotherapy department
School of Pharmacy
Virginia Commonwealth University

123

Internship:
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Academic Appointments(teaching):

As part of being a lecturer in the Department of Pharmacology and Clinical Research unit at King
Abdulaziz University
•
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